



Kingdom of Saudi Arabia
Saudi Health Council
National Health Information Center
Saudi Cancer Registry

Cancer Incidence Report
Saudi Arabia
2015



Kingdom of Saudi Arabia
Saudi Health Council
National Health Information Center
Saudi Cancer Registry

Cancer Incidence Report
Saudi Arabia
2015

Prepared by

Mr. Ahmed Alrawaji
Health Data Analyst and Quality Specialist

Mr. Zeyad Alshahrani
Health Data Analyst and Quality Specialist

Mrs. Wafa Alzahrani
Health Data Analyst and Quality Specialist

Mr. Fawaz Alomran
Health Data Analyst and Quality Specialist

Mrs. Amal Almadouj
Data Manager of Gulf Center for Cancer Control and
Prevention (KFSH&RC) - Adviser for Saudi Cancer
Registry

Reviewed by

Dr. Sulieman Alshehri
Consultant Public Health & Pediatrics
General Director of Saudi National Cancer Center

Dr. Ali Alzahrani
Principal Clinical Scientist/ Senior Consultant
Executive director, Gulf Center for Cancer Control and
Prevention (KFSH&RC)

Dr. Shouki Bazarbashi
Head, Section of Medical Oncology, Oncology
Center, King Faisal Specialist Hospital & Research
Center

Dr. Hani Alhashmi
Director, Oncology Center, Consultant Medical
Oncology, Hematology and Stem Cell Transplant

Dr. Hind Almutlaq
Director of National Health Registries

Mr. Khaled Sharaheli
Manager of Saudi Cancer Registry



ISSN: 616-992

Foreword

The Saudi Health Council (SHC) is pleased to present the 2015 annual report of cancer incidence in the Kingdom of Saudi Arabia, which is a collaborative effort by the team of Saudi Cancer Registry (SCR). SCR is a population-based registry that aims to define cancer incidence, prevalence and trends in Saudi Arabia in attempt to support clinical & epidemiological research and promote the evaluation process of relevant National programs and activities such as early detection and cancer screening.

Since 1994, SCR managing and analyzing cancer data from the different health sectors. All reported cancer data flows through an online system to the data management team in the central office of SCR for review, validation and analysis. The annual reports published by the Registry are demonstrating the geographical and demographic distribution of different types and stages of diagnosed cancer cases while the statistics demonstrate the trend of cancers over the past twenty years within Saudi Arabia.

In our efforts to align with 2030 Vision and satisfying the related strategic objective of National Transformation Program (NTP) 2020 “Promoting Public Health and Prevention”, we are in the process of reviewing the existing policies and rules with of National Registries in the kingdom in order to enhance governance process and utilize the outcomes of registries as a tool that inform the overall national healthcare decision as well as support policy makers to develop evidence informed health policies.

Finally, I would like to take the opportunity to thank all health institutions and healthcare providers who contribute effectively in reporting the needed data to formulate this annual report.

Special thanks to our partners, National Cancer Center, Gulf Center for Cancer Control and Prevention, Tumor registrars, and to the members of the SCR Advisory Committee. In addition, I would like to congratulate the main office team for the hard work during the last 8 months to get the report ready for all health care providers and researchers.

Dr. Ahmed Alamry
General Secretary
Saudi Health Council

Introduction

This is the nineteenth cancer incidence report published by the Saudi Cancer Registry. Previous publications include the Incidence Reports for the years 1994-1996, 1997-1998, 1999-2000 and yearly reports until 2014.

The structure of this report can be outlined as follows:

Part I- Materials and Methods

This part of the report contains information about the background of the Saudi Cancer Registry and methods used in collecting and analyzing the data. We present the basics of coding and classification of tumor topography, morphology and extent of disease at the time of diagnosis. Also we describe the software programs we have used to analyze the data.

Part II- Overview of Cancer Incidence

Part II contains figures and tables that show overall cancer incidence in Saudi Arabia for the year 2015. We present these figures and tables mainly by gender and in certain areas we have it analyzed by different age groups. There are bar charts representing the age distribution of cancer incidence for the year 2015 among Saudis by gender and age groups. We present incidence and morphology tables for the most common types of cancers among adults and children. In addition, tables, list the total number of cases, the Age-Standardized Incidence Rate (ASR) per 100,000 population, Crude Incidence Rate (CIR) and Cumulative rates by primary site and gender. Separate bar charts depict the most common types of cancer, by gender.

Part III- Cancer Incidence for Most Common Sites 2015

In this part the incidence of the most common cancers among Saudi males and females are outlined. A standardized layout presents data for all patients and

for both genders where applicable. For each selected site the number and the percentage of all newly diagnosed cases for the year 2015, the ASR for each gender and the specific cancer rank for both genders are presented. In addition, ASR for the specified cancer among Saudis is compared with ASR among other populations from selected countries

Part IV-Cancer Incidence among Non-Saudis

This part presents the incidence of cancer cases among Non-Saudis including the most common types of cancer. The analysis of the Non-Saudis is performed separately due to the nature of the expatriate population in Saudi Arabia in which large proportion aged between 25 and 44 years especially among male population.

Part V-Incidence Tables

Contains the following detailed tables for all newly diagnosed

cancer types among Saudis and Non-Saudis for 2015.

- Distribution of cancer cases among Saudis by age group and gender.
- Distribution of cancer cases among Non- Saudis by age group and gender.
- Cancer Incidence (per 100,000 populations) among Saudis by age group and gender.
- Cancer Incidence (per 100,000 populations) among Non-Saudis by age group and gender.
- Age-standardized incidence rate and relative frequencies among Saudis by cancer site, gender.

Part VI- Arabic Summary

Contains Arabic Summary of Cancer Statistics in Saudi Arabia for the Year 2015.

Table of contents

Foreword.....	4
Introduction.....	5
 PART I	 8
MATERIALS AND MOTHEDES	
Background on Saudi Arabia.....	9
Saudi Cancer Registry.....	9
Definitions of Statistical Terms.....	12
 PART II	 14
OVERVIEW OF CANCER INCIDENCE, 2015	
Cancer Incidence in Saudi Arabia, 2015.....	15
Cancer Distribution Among Saudi Nationals, 2015.....	17
Cancer Incidence Among Adults (> 14 Years), 2015.....	20
Childhood Cancer Reported to Saudi Cancer Registry ($\leq$ 14 Years), 2015.....	21
International Comparison of Age-Standardized Incidence Rates.....	25
 PART III	 26
CANCERS INCIDENCE FOR MOST COMMON SITES 2015	
Cancer Incidence for Most Common Sites, 2015.....	27
Female Breast Cancer (C50).....	28
Colorectal Cancer (C18-C20)	30
Thyroid Cancer (C73)	32
Non- Hodgkin's Lymphoma (C82-C85; C96)	34
Leukaemia (C91-C95)	36
Hodgkin's Lymphoma (C81)	38
Lung Cancer (C33-C34)	40
Corpus Uteri Cancer (C54)	42
Liver Cancer (C22)	44
Prostate Cancer (C61)	46
References.....	48
 PART IV	 49
CANCER AMONG NON-SAUDI 2015	
Cancer Incidence Among Non-Saudi Population. 2015.....	50
 PART V	 53
INCIDENCE TABLES	
Table 5.1.1 Number of Cases Among Saudi Male by Primary Site and Age Group, 2015.....	54
Table 5.1.2 Number of Cases Among Saudi Female by Primary Site and Age Group, 2015.....	55
Table 5.1.3 Age Specific Incidence Rate (AIR), Age Standardized Incidence Rate (ASR) Among.....	56
Saudi Male (per 100,000) By Primary Site and Age Group, 2015	

Table 5.1.4 Age Specific Incidence Rate (AIR), Age Standardized Incidence Rate (ASR) Among..... Saudi Female (per 100,000) By Primary Site and Age Group, 2015	57
Table 5.4.1 Number of Cases Among Non-Saudi Male by Primary Site and Age Group, 2015.....	58
Table 5.4.2 Number of Cases Among Non-Saudi Female by Primary Site and Age Group, 2015.....	59
Table 5.4.3 Age Specific Incidence Rate (AIR), Age Standardized Incidence Rate (ASR) Among Non-Saudi Male (per 100,000) By Primary Site and Age Groups, 2015	60
Table 5.4.4 Age Specific Incidence Rate (AIR), Age Standardized Incidence Rate (ASR) Among Non-Saudi Female (per 100,000) By Primary Site and Age Group	61
Acknowledgment.....	62
Arabic Summary.....	63



PART I

MATERIALS AND METHODS

Background on Saudi Arabia

Saudi Arabia is a vast country extending over four-fifths of the Arabian Peninsula. It stretches from the Arabian Gulf in the east to the Red Sea in the west. It is approximately 2,149,700* square kilometers in area and is divided into 13 administrative regions Figure 1.1 .




Figure 1.1: Administrative regions of Saudi Arabia

The estimated population for Saudi Arabia in 2015 was 31,062,072. Saudi nationals were estimated to be 19,863,975** of these 10,121,867 (51%) were males and 9,742,108 (%49) were females. The Non-Saudi population was 11,198,097 **, of these 7,696,791 (69%) were males and 3,501,306 (31%) were females. Figures 1.2 and 1.3 show the Saudi and Non- Saudi population pyramids by gender and age group respectively.

Figure 1.2: Population pyramids of Saudis (%) by gender and age group, 2015





Figure 1.3: Population pyramids of Non-Saudis (%) by gender and age group, 2015



Saudi cancer registry

The Saudi Cancer Registry (SCR) is a population-based registry established in 1992 under the authority of the Ministry of Health (MOH) in the premises of King Faisal Specialist Hospital and research Center in Riyadh. In 2014 SCR was moved to Saudi Health Council under the department of National Registries in National Center for Health Information.

Goals

The primary goal of the SCR were to determine the national cancer statistics in Saudi Arabia, to monitor cancer screening and early detection programs in collaboration with Saudi National Cancer Center, and to provide decision makers and researchers with reliable data.

Organizational structure

The SCR consists of the main office which oversees data collection from all over the country through five regional offices to ensure full coverage of all healthcare facilities in the Kingdom Figure 1.4 . The registry is supported by advisory committee.

The committee provides scientific guidance to the SCR and It reviews cancer statistics reports, data requests, and provides help in disseminating reliable information, and ensuring data confidentiality according to national and international guidelines.

* Source :Demographic and Health Indicators for Countries of the East Mediterranean, WHO, Regional Office for the EM,1999

** Source: General Authority for statistics, Saudi Arabia

Regional offices

1. Central Region: located at King Fahad Medical City in Riyadh, covering Riyadh, Qassim, and Hail Regions.
2. Eastern Region: located at King Fahad University Hospital in Al Khobar, covering Dammam, AlAhsa, and Hafr Al-Batin Governorates.
3. Western Region: located at East Jeddah General Hospital, covering Jeddah, Makkah, Taif and Qunfudah Governorates.
4. Southern Region: located at Asir Central Hospital in Abha, covering Asir, Baha, Najran, Jazan and Bisha Regions.
5. Madinah Region: located at Maternity and Children Hospital in Madinah, covering Madinah, Tabuk, Jouf and Northern Regions.

Each of the SCR office operates under regional directors who are responsible for the daily management. Staffing consists of senior and junior tumor registrars. SCR Main Office supervises regional offices to ensure accuracy and quality of data collected from all regions. Quality control processes include verification of site, morphology, and staging information as well as case linkage (tumor and patient), and consolidation of data. The Main Office also prepares annual reports for dissemination to the medical community, government departments, international organizations and public.

Saudi Cancer Registry Main Office

Central Region

(Riyadh, Qassim & Hail)

Eastern Region

(Dammam, Ahsa & Hafar Al Bain)

Western Region

(Jeddah, Makkah, Taif & Qunfudah)

Southern Region

(Asir, Baha, Jazan & Najran)

Madinah & Northern Region

(Madinah, Tabuk, Jouf & Northern Region)

Data management

A royal decree has categorized cancer as a mandatory notifiable disease. This ensures the opportunity for comprehensive data collection. The SCR strives for full access to cancer data from all Ministry of Health and other governmental and private hospitals, as well as clinics and laboratories throughout the Kingdom. Cancer data are abstracted from patients' medical records, based on clinical and/or histopathological diagnosis, by SCR trained cancer registrars. Abstracted data includes personal identifications (name, ID Number, gender, age), demographic information (address, telephone number, nationality), and tumor details (diagnosis date, primary site, histology, behavior, grade, stage, basis of diagnosis). The primary site (topography) and histology (morphology) of the malignancies are identified and coded according to the International Classification of Diseases for Oncology 3rd Edition (ICD-O-3), published by the World Health Organization (WHO), 2000. Effective from year 2001, changes were made in coding of cancer types and behaviors as well as staging according to SEER Summary Stage 2000 to increase accuracy and consistency in stage coding. SEER Summary Stage Manual 2000 is available on the web

at: <http://seer.cancer.gov/tools/ssm/>

Cases diagnosed on or after 01 January 2008 were classified according to the updated ICD-O-3. While there have not been any changes in the primary site codes, there are significant changes regarding histology (cell types). Leukemia and lymphoma, particularly are affected. Some cases that were previously considered benign are now counted as malignant. Also small number of cancers that were previously coded as borderline tumors are now considered benign. Counts of ovarian cancers, lymphoma and leukemia as well as some hematopoietic diseases will change due to changes in either report ability or definition. However, as with the SEER staging guidelines, the ICD-O changes reflect advances in the understanding of the pathology and behavior of cancers. It should be noted that ICD-O-3 codes are converted to ICD-10 for analysis purposes. Since the WHO has not yet converted ICD-10 hematopoietic disease behavior changes, our software, CanReg 4.33 (developed by the International Agency for Research on Cancer (IARC), Lyon, France) cannot include

these cases for analysis and they have been excluded. Every effort is made to accurately code patient and tumor information, to ensure that all data can be reviewed, linked, and consolidated, as appropriate, so that each malignancy is counted only once for statistical analysis. Data entry and incidence tables output were generated by CanReg software.

The second part of the report includes the overall cancer incidence in Saudi Arabia and the relevant epidemiological and clinic pathological details for the 10 most common cancers among Saudi nationals for the year 2015. For each cancer site, absolute numbers, percentages, age-standardized incidence rate (ASR) per 100,000 populations for each gender, and specific cancer rank in comparison to all cancers and with some selected developed and developing countries for both genders are presented.

For each cancer site, five figures are generated:

1. Arithmetic line graph representing age-specific incidence rate (AIR) for each gender by five-year age groups.
2. Table listing percentages of the most common histology sub-types.
3. Pie chart showing the distribution of SEER summary staging i.e. localized, regional, distant metastasis, and unknown stage.
4. Bar chart showing regional distribution of ASR for particular cancer by gender.
5. Bar chart with comparisons of age-standardized incidence rates (ASR) for each cancer type in Saudi Arabia and some other countries.

Notification

This report covers data that were diagnosed between January and December 2015. Incident cases identified after this date (late reporting) will be reported in subsequent incidence reports. It is anticipated that the number of late-reported cases will decrease as case ascertainment processes has improved during past years. Our aim is reduce reporting lap between year of diagnosis and year of publishing the incidence report to a maximum of 2 years while maintaining high quality and completeness of data.

Definitions of Statistical Terms

Age-Specific Incidence Rate (AIR)

The number of cancer cases occurring during a specific period in a population of a specific age and gender group, divided by the number of midyear population of that age and gender group.

Age-Standardized Rate (ASR)

The Age-standardized rate is a summary measure of a rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age structure. The most frequently used standard population is the World Standard Population (see below). The calculated incidence is known as the World Standardized Incidence Rate. The rate is expressed per 100,000 populations.

World Standard Population

Age Class	Population
0-4	12.000
5-9	10.000
10-14	9.000
15-19	9.000
20-24	8.000
25-29	8.000
30-34	6.000
35-39	6.000
40-44	6.000
45-49	6.000
50-54	5.000
55-59	4.000
60-64	4.000
65-69	3.000
70-74	2.000
75+	2.000
Total	100.000

* Doll R, Payne P, Waterhouse J. Cancer Incidence in Five Continents Vol. I. International Union against Cancer, 1966

Crude Incidence Rate (CIR)

The crude incidence rate for a cancer site is the total number of cases registered as a proportion of the total population. It denotes the approximate number of cases occurring in each 100,000 individuals. All rates are thus, expressed as per 100,000 population. Cancer rates vary greatly with age and the crude rate is strongly influenced by the demographic structure of the population. Hence, if the population structure changes over time the crude rate over that period may be artificially altered. It is not appropriate to compare crude rates across geographical areas of cancer registries with different population age structures. Therefore, in order to assess time trends in registration data or compare incidence across geographical areas or between registries it is necessary to first standardize the rates with respect to age.

Cumulative incidence rate

Cumulative incidence rate is the probability or risk of individuals developing the disease during a specified period. For cancer, it is expressed as the number of new born children (out of 100, or 1000) who would be expected to develop a particular cancer before the age of 65 (or 70, or 75) if they had the rates of cancers currently observed. Like the age standardized rate, it permits comparison between populations of different age structures. In this report the age ranges 0-64 and 0-74 years are used. The cumulative rate is the summation of the cancer age-specific rates; which are computed for five-year age intervals.

ICD - 10

The World Health Organization's International Classification of Diseases, tenth edition.

ICD - O - 3

The World Health Organization's International Classification of Diseases for Oncology, 3rd Edition has been the standard coding system for neoplasms for over 25 years. The coding system includes a four character code for primary site, a four-digit numeric code for cell type, one-digit code for behavior and a one-digit code for tumor aggressiveness (grade).

Incidence rate

An incidence rate is defined as the rate at which a new event occurs in a population. It is calculated as the number of new cases of disease arising in a population over a defined time period, divided by the population at risk of developing that disease.

Mean

The simple mathematical average of two or more numbers.

Median

The midpoint of the range numbers that are arranged in order of value.

Metastasis

Metastasis is the distant spread of cancer from its original site to other organs of the body, including lymph nodes, skeletal and or visceral organs.

Range

It is the difference between the maximum and minimum values in a set of observations.

Rank

This measure reflects the importance of a specific cancer site relative to other sites, in terms of the number of registrations. Ranking illustrates the most and least frequent cancer sites in a population according to their frequency.

Ratio

It is the relation between two quantities. The first quantity as numerator and the second as denominator.

Relative frequency

This statistic is defined as the number of specific cancer cases registered relative to the total number of all cancer. It is expressed as a percentage.

Summary Stage

Staging is the grouping of cancer cases into broad categories based on the extent of the disease.



PART II

OVERVIEW OF CANCER INCIDENCE

2015

Cancer Incidence in Saudi Arabia, 2015

Between January 01 and December 31, 2015, the total number of newly diagnosed cancer cases reported to the Saudi Cancer Registry (SCR) was 16,210. Overall cancer was more among women than men; it affected 8,565 (52.8%) females and 7,645 (47.2%) males. Total of 12,038 cases were reported among Saudi nationals, 3,504 among non-Saudi, and 142 of unknown nationality.

Total of 668 cases were excluded from the analysis: 142 cases of them were unknown nationalities, and 526 cases failed to be converted to ICD-10 codes. The software (CanReg-4) does not include in situ cases in the statistical analysis, **Table 2.1**.

Total of 15,542 cases were analyzed, of which 12,038 (77.5%) were Saudi nationals and 3,504 (22.5%) were Non-Saudi. Among Saudis 5,454 (45.3%) were males and 6,584 (54.7%) were females with a male to female ratio of 100 to 120.


The crude incidence rates (CIR) of all cancers were 53.9/100,000 in males and 67.6/100,000 in females. The overall age-standardized incidence rate (ASR) was 70.7/100,000 in males and 83.3/100,000 in females.

Table 2.1: Distribution of analyzed and non-analyzed cancer cases reported to Saudi Cancer Registry by Nationality and Gender 2015

Saudis						Unknown Nationality			Non-Saudis					
Analyzed			Non Analyzed						Analyzed			Non Analyzed		
Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
5454	6584	12038	200	163	363	71	71	142	1816	1688	3504	104	59	163

The age-specific incidence rate (AIR) increased with advancing age in both genders. The median age at diagnosis was 57 years with a range of (0 -109) for males, and 52 years with a range of (0-114) for female, **Figure 2.2**.

Figure 2.2: Age-Specific Incidence Rate (AIR) for all cancers among Saudis, 2015



Confirmation of malignancy was based mainly on histopathology reports (85.3%), followed by hematological and cytological reports (6.1%), then histology of metastases (4.4%), then medical imaging reports (2.4%), and death certificate only (1.4%). Other sources such as surgical and clinical notes and laboratory tests for tumor markers were the source in less than (0.5%), and unknown source was present in (0.2%) of cases, **Table 2.3**.

Table 2.3: Basis of diagnosis for all cancer cases among Saudi Nationals, 2015

Basis of diagnosis	No	%
Histology of primary	10271	85.3
Cytology/Haematological	732	6.1
Histology of metastases	532	4.4
Medical Imaging (Xray,US)	284	2.4
DCO (Death Certificate)	167	1.4
Unknown	20	0.2
Clinical	22	0.2
Laboratory test (Tumor Marker)	9	0.1
Surgery	1	0.0
Total	12038	100.0

Cancer Distribution Among Saudi Nationals, 2015

In females the highest number of cases reported at the age group of 45-59 years, total of 2232 (33.9%) cancer cases reported in 2015. Whereas, in males the highest number of cases reported at the age group of 60-74 years, total of 1469 (26.9%) cancer cases reported in 2015, Figure 2.3.

Figure 2.3: Distribution of cancer cases among Saudi nationals by gender and age group, 2015




Figure 2.4: Distributions of most frequent types of cancer among Saudi nationals by gender and age group, 2015

Table 2.4: Most common cancers among Saudi nationals, 2015

Sites	No.	%
Breast	2016	16.7
Colorectal	1465	12.2
Thyroid	1020	8.5
NHL	829	6.9
Leukaemia	702	5.8
Hodgkin's lymphoma	436	3.6
Lung	416	3.5
Corpus Uteri	403	3.3
Liver	376	3.1
Prostate	340	2.8

Table 2.5: Most common cancers among Saudi nationals by gender, 2015

Male	5454	%	Female	6584	%
Colorectal	810	14.9	Breast	1979	30.1
NHL	503	9.2	Thyroid	793	12.0
Leukaemia	408	7.5	Colorectal	655	9.9
Prostate	340	6.2	Corpus Uteri	403	6.1
Lung	324	5.9	NHL	326	5.0
Liver	274	5.0	Leukaemia	294	4.5
Hodgkin's lymphoma	267	4.9	Ovary	220	3.3
Thyroid	227	4.2	Hodgkin's lymphoma	169	2.6
Kidney	199	3.6	Stomach	131	2.0
Brain, CNS	194	3.6	Brain, CNS	126	1.9

Table 2.6: Number, percentage, ASR, CIR and Cumulative Rates (per 100,000) among Saudi Nationals by primary cancer site and gender, 2015

ICD-10	Site	Male						Female					
		No.	%	Crude Rate	ASR World	Cumulative Rate		No.	%	Crude Rate	ASR World	Cumulative Rate	
						0-64	0-74					0-64	0-74
All	All sites Total	5454	100.00	53.9	70.7	36.7	77	6584	100.00	67.6	83.3	56.7	92.3
Not C44	All sites but C44	5245	96.20	51.9	68	35.55	74.35	6446	97.90	66.2	81.4	55.7	90.15
C00	Lip	10	0.20	0.1	0.2	0.085	0.155	3	0.00	0	0	0.01	0.04
C01-C02	Tongue	34	0.60	0.3	0.5	0.235	0.59	29	0.40	0.3	0.4	0.165	0.575
C03-C06	Mouth	52	1.00	0.5	0.7	0.36	0.81	47	0.70	0.5	0.7	0.435	0.76
C07-C08	Salivary glands	23	0.40	0.2	0.3	0.17	0.215	17	0.30	0.2	0.2	0.15	0.225
C09	Tonsil	7	0.10	0.1	0.1	0.03	0.11	0	0.00	0	0	0	0
C10	Other Oropharynx	3	0.10%	0	0	0.025	0.025	1	0.00	0	0	0	0.03
C11	Nasopharynx	128	2.30	1.3	1.5	1.17	1.525	46	0.70	0.5	0.5	0.35	0.535
C12-C13	Hypopharynx	5	0.10	0	0.1	0.005	0.085	7	0.10	0.1	0.1	0.085	0.16
C14	Pharynx unspec.	1	0.00	0	0	0.01	0.01	1	0.00	0	0	0.015	0.015
C15	Oesophagus	74	1.40	0.7	1.1	0.285	1.21	56	0.90	0.6	0.8	0.345	0.84
C16	Stomach	185	3.40	1.8	2.6	1.035	2.87	131	2.00	1.3	1.7	0.975	1.805
C17	Small intestine	37	0.70	0.4	0.5	0.28	0.51	18	0.30	0.2	0.3	0.17	0.375
C18	Colon	475	8.70	4.7	6.6	3.74	7.79	420	6.40	4.3	5.8	3.925	6.79
C19-C20	Rectum	335	6.10	3.3	4.6	2.835	5.67	235	3.60	2.4	3.3	2.225	4.21
C21	Anus	17	0.30	0.2	0.2	0.145	0.32	9	0.10	0.1	0.1	0.065	0.13
C22	Liver	274	5.00	2.7	4	1.625	4.465	102	1.50	1	1.5	0.825	1.82
C23-C24	Gallbladder etc.	82	1.50	0.8	1.2	0.5	1.425	87	1.30	0.9	1.3	0.63	1.695
C25	Pancreas	151	2.80	1.5	2.2	1.2	2.75	95	1.40	1	1.4	0.825	1.83
C30-C31	Nose, sinuses etc.	17	0.30	0.2	0.2	0.105	0.205	11	0.20	0.1	0.1	0.045	0.12
C32	Larynx	77	1.40	0.8	1.2	0.55	1.545	16	0.20	0.2	0.2	0.15	0.27
C33-C34	Trachea,Bronchus,Lung	324	5.90	3.2	4.8	2.325	5.975	92	1.40	0.9	1.3	0.665	1.775
C37-C38	Other Thoracic organs	20	0.40	0.2	0.2	0.09	0.265	10	0.20	0.1	0.1	0.1	0.1
C40-C41	Bone	70	1.30	0.7	0.7	0.44	0.52	48	0.70	0.5	0.5	0.285	0.44
C43	Melanoma of Skin	14	0.30	0.1	0.2	0.095	0.19	15	0.20	0.2	0.2	0.065	0.23
C44	Other Skin	209	3.80	2.1	2.7	1.11	2.67	138	2.10	1.4	1.9	0.845	2.055
C45	Mesothelioma	9	0.20	0.1	0.1	0.04	0.17	4	0.10	0	0.1	0.055	0.055
C46	Kaposi sarcoma	28	0.50	0.3	0.4	0.13	0.415	1	0.00	0	0	0	0.045
C47,C49	Connective,Soft tissue	87	1.60	0.9	0.9	0.6	0.765	63	1.00	0.6	0.7	0.485	0.64
C50	Breast	37	0.70	0.4	0.5	0.275	0.53	1979	30.10	20.3	24.3	19.11	26.615
C51	Vulva	--	--	--	--	--	--	8	0.10	0.1	0.1	0.095	0.095
C52	Vagina	--	--	--	--	--	--	10	0.20	0.1	0.1	0.065	0.13
C53	Cervix Uteri	--	--	--	--	--	--	102	1.50	1	1.3	0.99	1.47
C54	Corpus Uteri	--	--	--	--	--	--	403	6.10	4.1	5.9	3.87	7.61
C55	Uterus unspec.	--	--	--	--	--	--	27	0.40	0.3	0.4	0.225	0.52
C56	Ovary	--	--	--	--	--	--	220	3.30	2.3	2.8	1.605	3.105
C57	Other Female Genital	--	--	--	--	--	--	9	0.10	0.1	0.1	0.07	0.16
C58	Placenta	--	--	--	--	--	--	5	0.10	0.1	0	0.035	0.035
C60	Penis	1	0.00	0	0	0.01	0.01	--	--	--	--	--	--
C61	Prostate	340	6.20	3.4	5.4	1.495	6.77	--	--	--	--	--	--
C62	Testis	102	1.90	1	0.9	0.62	0.62	--	--	--	--	--	--
C63	Other male genital	4	0.10	0	0	0.04	0.04	--	--	--	--	--	--
C64	Kidney	199	3.60	2	2.6	1.565	3.03	116	1.80	1.2	1.5	0.985	1.765
C65	Renal Pelvis	4	0.10	0	0.1	0.015	0.05	2	0.00	0	0	0.005	0.035
C66	Ureter	3	0.10	0	0	0.025	0.07	0	0.00	0	0	0	0
C67	Bladder	192	3.50	1.9	2.8	1.09	3.425	47	0.70	0.5	0.7	0.42	0.735
C68	Other Urinary organs	2	0.00	0	0	0.035	0.035	0	0.00	0	0	0	0
C69	Eye	21	0.40	0.2	0.2	0.105	0.15	17	0.30	0.2	0.2	0.075	0.12
C70-C72	Brain, Nervous system	194	3.60	1.9	2.2	1.43	2.12	126	1.90	1.3	1.5	1.095	1.375
C73	Thyroid	227	4.20	2.2	2.5	1.84	2.38	793	12.00	8.1	8.4	6.54	8.175
C74	Adrenal gland	15	0.30	0.1	0.2	0.07	0.07	22	0.30	0.2	0.2	0.125	0.125
C75	Other Endocrine	7	0.10	0.1	0.1	0.035	0.035	4	0.10	0	0	0.03	0.03
C81	Hodgkin disease	267	4.90	2.6	2.6	1.69	2.115	169	2.60	1.7	1.7	1.225	1.44
C82-C85,C96	Non-Hodgkin lymphoma	503	9.20	5	5.9	3.46	5.935	326	5.00	3.3	4.1	2.49	4.455
C88	Immunoproliferative dis.	0	0.00	0	0	0	0	0	0.00	0	0	0	0
C90	Multiple Myeloma	55	1.00	0.5	0.7	0.41	0.835	50	0.80	0.5	0.7	0.31	1.025
C91	Lymphoid Leukaemia	203	3.70	2	2.2	1.095	1.465	113	1.70	1.2	1.3	0.68	0.9
C92-C94	Myeloid Leukaemia	182	3.30	1.8	2	1.16	1.93	168	2.60	1.7	1.9	1.27	1.75
C95	Leukaemia unspec.	23	0.40	0.2	0.3	0.105	0.27	13	0.20	0.1	0.2	0.06	0.17
Other	Other & unspecified	125	2.30	1.2	1.7	0.825	1.79	153	2.30	1.6	2.2	1.24	2.695

Cancer Incidence among Adults (>14 years), 2015

Between January and December 2015, the total number of cancer incidence cases reported to the Saudi Cancer registry among adults aged above 14 years was 15,374. Of those, 11,671 cancer cases were among Saudis and 3,565 were among non-Saudis, and unknown nationality was reported in 138 cases. Total of 7,167 (46.6%) cases were males and 8,207(53.4%) were females with a male to female ratio of 100 to 114, **Table 2.7.1**.

Table 2.7.1: Distribution of analyzed and non-analyzed adult cancer cases reported to Saudi Cancer Registry by Nationality and Gender, 2015

Saudis						Unknown Nationality			Non-Saudis					
Analyzed			Non Analyzed						Analyzed			Non Analyzed		
Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
5036	6275	11311	199	161	360	68	70	138	1760	1642	3402	104	59	163

Table 2.7.2: Most common cancers among Saudi adults, 2015

Site	No.	%
Breast	2015	17.8
Colorectal	1463	12.9
Thyroid	1009	8.9
NHL	740	6.5
Leukaemia	447	4.0
Lung	415	3.7
Corpus Uteri	403	3.6
Hodgkin's lymphoma	370	3.3
Liver	367	3.2
Prostate	340	3.0

Table 2.7.3: Top ten cancers reported among Saudi Adults by gender, 2015

Male			Female		
	5036	%		6275	%
Colorectal	808	16.0	Breast	1978	31.5
NHL	437	8.7	Thyroid	785	12.5
Prostate	340	6.7	Colorectal	655	10.4
Lung	323	6.4	Corpus Uteri	403	6.4
Liver	266	5.3	NHL	303	4.8
Leukaemia	262	5.2	Ovary	208	3.3
Hodgkin's lymphoma	226	4.5	Leukaemia	185	2.9
Thyroid	224	4.4	Hodgkin's lymphoma	144	2.3
Bladder	192	3.8	Stomach	131	2.1
Stomach	184	3.7	Cervix Uteri	102	1.6

Childhood cancers reported to Saudi Cancer Registry (≤ 14 years), 2015

Total of 836 cancer cases were diagnosed among children aged between 0 and 14 years accounted to 5.2% of the total number of cancers reported to Saudi Cancer Registry in 2015. The reported incidents show that cancer was more common among boys than girls, 478 (57.2%) cases were reported among boys and 358 (42.8%) among girls. Total of 730 cancer cases were reported among Saudi children, 102 were among non-Saudis, and 4 cases were with unknown nationality. The total number of analyzed cases were 829 including 727 Saudis, and 102 non-Saudis. Among Saudi, 418 (57.6%) were boys and 309 (42.4%) were girls, **Table 2.8.1**.

Table 2.8.1: Distribution of reported childhood cancer in Saudi Arabia by nationality and Gender, 2015

Saudis						Unknown Nationality			Non-Saudis					
Analyzed			Non Analyzed						Analyzed			Non Analyzed		
Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
418	309	727	1	2	3	3	1	4	56	46	102	0	0	0

Childhood cancers accounted for 6.0% of all cancer among Saudis. The leading cancer among Saudi children was Leukaemia (35.0 %), followed by Brain, CNS tumors (12.2%), then NHL (12.2%) and Hodgkin's lymphoma (9.1%), **Table 2.8.2**.

Table 2.8.2: Top ten cancers among Saudi Children, 2015

Site	No.	%
Leukaemia	255	35.0
Brain, CNS	89	12.2
NHL	89	12.2
Hodgkin's lymphoma	66	9.1
Kidney	43	5.9
Bone	32	4.4
Adrenal gland	28	3.8
Eye	26	3.6
Connective,Soft tissue	23	3.2
Ovary	12	1.6

Table 2.8.3: and **Table 2.8.4** show the distribution of the top ten cancer sites for boys and girls and the common morphological types.

Boy	(418)	%	Girl	(309)	%
Leukaemia	146	34.8	Leukaemia	109	35.3
NHL	66	15.8	Brain, CNS	38	12.3
Brain, CNS	51	12.2	Hodgkin's lymphoma	25	8.1
Hodgkin's lymphoma	41	9.8	Kidney	24	7.8
Kidney	19	4.5	NHL	23	7.4
Bone	15	3.6	Bone	17	5.5
Eye	15	3.6	Adrenal gland	15	4.9
Connective, Soft tissue	14	3.3	Ovary	12	3.9
Adrenal gland	13	3.1	Eye	11	3.6
Liver	8	1.9	Connective, Soft tissue	9	2.9

Table 2.8.4: Distribution of morphological types for the most common cancers reported among Saudi children by gender, 2015

Primary Site	Code	Morphology	Male	%	Female	%
leukaemia	98363	Precursor B-cell lymphoblastic leukaemia	77	52.7	57	52.3
	98353	Precursor cell lymphoblastic leukaemia, NOS	16	11.0	9	8.3
	98373	Precursor T-cell lymphoblastic leukaemia	15	10.3	2	1.8
	98613	Acute myeloid leukaemia, NOS	12	8.2	19	17.4
	98263	Burkitt cell leukaemia	4	2.7	1	0.9
	98013	Acute leukaemia, NOS	3	2.1	5	4.6
	99103	Acute megakaryoblastic leukaemia	3	2.1	2	1.8
	98003	leukaemia, NOS	2	1.4	1	0.9
	98633	Chronic myeloid leukaemia, NOS	2	1.4	3	2.8
	98673	Acute myelomonocytic leukaemia	2	1.4	0	0.0
	98913	Acute monocytic leukaemia	2	1.4	2	1.8
	99303	Myeloid sarcoma	2	1.4	1	0.9
		Others	6	3.9	7	6.0
		Total	146	99.8	109	99.6
Brain, CNS	94703	Medulloblastoma, NOS	24	47.1	12	31.6
	93803	Glioma, malignant	4	7.8	2	5.3
	93923	Ependymoma, anaplastic	4	7.8	5	13.2
	95083	Atypical teratoid/rhabdoid tumor	4	7.8	0	0.0
	94403	Glioblastoma, NOS	2	3.9	4	10.5
	90643	Germinoma	2	3.9	0	0.0
	93913	Ependymoma, NOS	2	3.9	2	5.3
	94003	Astrocytoma, NOS	2	3.9	1	2.6
	93643	Peripheral neuroectodermal tumor	1	2.0	0	0.0
	95383	Papillary meningioma	1	2.0	0	0.0
	94503	Oligodendroglioma, NOS	1	2.0	0	0.0
		Others	4	7.8	12	31.6
		Total	51	100.0	38	100.0
NHL	96873	Burkitt lymphoma, NOS	18	27.3	6	26.1
	96803	Malignant lymphoma, large B-cell, diffuse, NOS	15	22.7	3	13.0
	97283	Precursor B-cell lymphoblastic lymphoma	10	15.2	2	8.7
	97293	Precursor T-cell lymphoblastic lymphoma	5	7.6	1	4.3
	97543	Langerhans cell histiocytosis, disseminated	4	6.1	4	17.4
	97023	Mature T-cell lymphoma, NOS	3	4.5	0	0.0
	97143	Anaplastic large cell lymphoma, T cell and Null cell type	3	4.5	3	13.0
	97003	Mycosis fungoides	2	3.0	2	8.7
	97273	Precursor cell lymphoblastic lymphoma, NOS	1	1.5	1	4.3
	97193	NK/T-cell lymphoma, nasal and nasal-type	1	1.5	0	0.0
	95903	Malignant lymphoma, NOS	1	1.5	1	4.3
		Others	3	4.3	0	0.0
		Total	66	100.0	23	100.0

Primary Site	Code	Morphology	Male	%	Female	%
Hodgkin lymphoma	96633	Hodgkin lymphoma, nodular sclerosis, NOS	19	46.3	12	48.0
	96503	Hodgkin lymphoma, NOS	7	17.1	3	12.0
	96593	Hodgkin lymphoma, nodular lymphocyte predominance	6	14.6	5	20.0
	96523	Hodgkin lymphoma, mixed cellularity, NOS	6	14.6	4	16.0
	96513	Hodgkin lymphoma, lymphocyte-rich	2	4.9	1	4.0
	97023	Mature T-cell lymphoma, NOS	1	2.4	0	0.0
		Total	41	100.0	25	100.0
Kidney	89603	Nephroblastoma, NOS	19	100.0	20	83.3
	88003	Sarcoma, NOS	0	0.0	1	4.2
	95003	Neuroblastoma, NOS	0	0.0	1	4.2
	89903	Mesenchymoma, malignant	0	0.0	1	4.2
	89103	Embryonal rhabdomyosarcoma, NOS	0	0.0	1	4.2
		Total	19	100.0	24	100.0
Bone	92603	Ewing sarcoma	9	60.0	7	41.2
	91803	Osteosarcoma, NOS	4	26.7	6	35.3
	93713	Chondroid chordoma	1	6.7	0	0.0
	91813	Chondroblastic osteosarcoma	1	6.7	1	5.9
	91833	Telangiectatic osteosarcoma	0	0.0	1	5.9
	90853	Mixed germ cell tumor	0	0.0	1	5.9
	91863	Central osteosarcoma	0	0.0	1	5.9
		Total	15	100.0	17	100.0
Adrenal gland	95003	Neuroblastoma, NOS	13	100.0	15	100.0
		Total	13	100.0	15	100.0
Eye	95103	Retinoblastoma, NOS	8	53.3	6	54.5
	95123	Retinoblastoma, undifferentiated	3	20.0	1	9.1
	95133	Retinoblastoma, diffuse	2	13.3	1	9.1
	80043	Malignant tumor, spindle cell type	1	6.7	0	0.0
	95113	Retinoblastoma, differentiated	1	6.7	3	27.3
		Total	15	100.0	11	100.0

Primary Site	Code	Morphology	Male	%	Female	%
Connective,Soft tissue	89003	Rhabdomyosarcoma, NOS	3	21.4	1	11.1
	95003	Neuroblastoma, NOS	3	21.4	2	22.2
	89103	Embryonal rhabdomyosarcoma, NOS	3	21.4	3	33.3
	90803	Teratoma, malignant, NOS	1	7.1	0	0.0
	90403	Synovial sarcoma, NOS	1	7.1	0	0.0
	88143	Infantile fibrosarcoma	1	7.1	0	0.0
	88103	Fibrosarcoma, NOS	1	7.1	0	0.0
	80103	Carcinoma, NOS	1	7.1	0	0.0
	93643	Peripheral neuroectodermal tumor	0	0.0	1	11.1
	80003	Neoplasm, malignant	0	0.0	1	11.1
	89203	Alveolar rhabdomyosarcoma	0	0.0	1	11.1
		Total	14	100.0	9	100.0
Ovary	90603	Dysgerminoma	0	0	3	25.0
	91003	Choriocarcinoma, NOS	0	0	2	16.7
	90803	Teratoma, malignant, NOS	0	0	2	16.7
	90713	Yolk sac tumor	0	0	2	16.7
	90853	Mixed germ cell tumor	0	0	1	8.3
	90703	Embryonal carcinoma, NOS	0	0	1	8.3
	84803	Mucinous adenocarcinoma	0	0	1	8.3
		Total	0	0	12	100.0

International Comparison of Age-Standardized Incidence Rates

Figure 2.6.1: Comparison of ASR* for Saudi male with selected countries**





Figure 2.6.2: Comparison of ASR* for Saudi female with selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56



PART III

INCIDENCE OF MOST COMMON
CANCERS DIAGNOSED AMONG SAUDI
NATIONALS, 2015

Cancer Incidence for Most Common Sites among Saudi Nationals, 2015

This section demonstrates the most common cancers diagnosed among Saudi nationals during the period between January and December 2015. It shows the distribution of the most common cancers by genders and geographical area. Data presented as absolute numbers, relative frequency, and incidence rates. It also presents comparisons of cancer incidence among Saudis compared to cancer incidence reported from selected developed and developing countries.

Table 3.1: Most common cancer among Saudis by gender, 2015

Site	Male	Female	All	%
Breast	37	1979	2016	16.7
Colorectal	810	655	1465	12.2
Thyroid	227	793	1020	8.5
NHL	503	326	829	6.9
Leukaemia	408	294	702	5.8
Hodgkin's lymphoma	267	169	436	3.6
Lung	324	92	416	3.5
Corpus Uteri	0	403	403	3.3
Liver	274	102	376	3.1
Prostate	340	0	340	2.8

Female Breast Cancer (C50)

Breast cancer ranked the 1st among females, between January and December 2015, there were 1,979 female breast cancer cases. Breast cancer accounted to 16.7% from all cancers reported among Saudi nationals, and 30.1% from all cancers reported among females at all ages. The ASR was 24.3/100,000 for Saudi female population. The median age at diagnosis was 50 years (Ranged between 14 and 108 years).

Figure 3.1.1: Age-Specific Incidence Rate (AIR) for breast cancer among Saudi females, 2015




Table 3.1.1: Morphological distribution of breast cancer among Saudi females, 2015

ICD-O-3	Morphology	No.	%
8500	Infiltrating duct carcinoma, NOS	1568	79.2
8520	Lobular carcinoma, NOS	147	7.4
8522	Infiltrating duct and lobular carcinoma	54	2.7
8010	Carcinoma, NOS	40	2.0
8523	Infiltrating duct mixed with other types of carcinoma	30	1.5
8480	Mucinous adenocarcinoma	19	1.0
8001	Tumor cells, malignant	18	0.9
8510	Medullary carcinoma, NOS	16	0.8
8140	Adenocarcinoma, NOS	15	0.8
9020	Phyllodes tumor, malignant	11	0.6
	Others	61	3.1

Figure 3.1.2: Stage distribution of breast cancer among Saudi females, 2015





Figure 3.1.4: Comparison of ASR* for breast cancer among Saudi female nationals with selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56

Colorectal Cancer (C18-C20)

There were 1,465 cases of colorectal cancer accounting for 12.2% of all newly diagnosed cases in year 2015 among Saudi nationals. Colorectal cancer ranked first among males and third among females. It affected 810 (55.3%) males and 655 (44.7%) females with a male to female ratio of 124:100. The ASR was 11.2/100,000 for males and 9.1/100,000 for females. The median age at diagnosis was 59 years in males (ranged between 8 and 94 years) and 57 years in females (ranged between 15 and 102 years).

Figure 3.2.1: Age-Specific Incidence Rate (AIR) for Colorectal Cancer among Saudi nationals, 2015




Table 3.2.1: Morphological distribution of colorectal cancer among Saudi nationals, 2015

Code	Morphology	Male	%	Female	%
81403	Adenocarcinoma, NOS	644	79.5	537	82.0
84803	Mucinous adenocarcinoma	65	8.0	44	6.7
80103	Carcinoma, NOS	17	2.1	7	1.1
84903	Signet ring cell carcinoma	14	1.7	12	1.8
82633	Adenocarcinoma in tubulovillous adenoma	13	1.6	8	1.2
80013	Tumor cells, malignant	9	1.1	3	0.5
82613	Adenocarcinoma in villous adenoma	9	1.1	11	1.7
84813	Mucin-producing adenocarcinoma	8	1.0	7	1.1
82463	Neuroendocrine carcinoma, NOS	6	0.7	4	0.6
81443	Adenocarcinoma, intestinal type	5	0.6	6	0.9
	Others	20	2.5	16	2.4

Figure 3.2.2: Stage distribution of colorectal cancer among Saudi nationals, 2015





Figure 3.2.4: Comparison of ASR* for colorectal cancer among Saudi nationals with selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56

Thyroid cancer (C73)

Thyroid cancer ranked second among Saudi females and eighth among Saudi males. There were 1020 thyroid cancer cases accounting to 8.5 % from all newly diagnosed cancers in 2015 among Saudi nationals. Thyroid cancer affected 793 (77.7%) females and 227 (22.3%) males; with a female to male ratio of 349:100. The ASR was 8.4/100,000 for females and 2.5/100,000 for males.

The median age at diagnosis was 39 years in females (ranged between 4 and 95 years) and 44 years in males (ranged between 8 and 95 years).

Figure 3.3.1: Age-Specific Incidence Rate (AIR) for thyroid cancer among Saudi nationals, 2015




Table 3.3.1: Morphological distribution of thyroid cancer among Saudi nationals, 2015

Code	Morphology	Male	%	Female	%
82603	Papillary adenocarcinoma, NOS	117	51.5	386	48.7
83403	Papillary carcinoma, follicular variant	26	11.5	152	19.2
83413	Papillary microcarcinoma	29	12.8	98	12.4
80503	Papillary carcinoma, NOS	12	5.3	28	3.5
83433	Papillary carcinoma, encapsulated	7	3.1	26	3.3
83303	Follicular adenocarcinoma, NOS	4	1.8	23	2.9
83443	Papillary carcinoma, columnar cell	2	0.9	18	2.3
83353	Follicular carcinoma, minimally invasive	3	1.3	16	2.0
82903	Oxyphilic adenocarcinoma	6	2.6	10	1.3
85103	Medullary carcinoma, NOS	7	3.1	6	0.8
	Others	14	6.2	30	3.8

Figure 3.3.2: Stage distribution of thyroid cancer among Saudi nationals, 2015





Figure 3.3.4: Comparison of ASR* for thyroid cancer among Saudi nationals with selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56

Non-Hodgkin Lymphoma (C82-C85; C96)

Non-Hodgkin Lymphoma (NHL) ranked second among males and fifth among females. There were 829 cases accounted to 6.9% from all cancers diagnosed among Saudi nationals in 2015. NHL affected 503 (60.7%) males, and 326 (39.3%) females, with a male to female ratio of 154:100. The ASR was 5.9/100,000 for males and 4.1/100,000 for females. The median age at diagnosis was 47 years in males (ranged between 0 and 100 years) and 55 years in females (ranged between 1 and 93 years).

Figure 3.4.1: Age-Specific Incidence Rate (AIR) for NHL among Saudi nationals, 2015




Table 3.4.1: Morphological distribution of NHL among Saudi nationals, 2015

Code	Morphology	Male	%	Female	%
96803	Malignant lymphoma, large B-cell, diffuse, NOS	240	47.7	181	55.5
96873	Burkitt lymphoma, NOS	32	6.4	11	3.4
95903	Malignant lymphoma, NOS	31	6.2	19	5.8
97003	Mycosis fungoides	27	5.4	16	4.9
95913	Malignant lymphoma, non-Hodgkin, NOS	19	3.8	12	3.7
97283	Precursor B-cell lymphoblastic lymphoma	17	3.4	5	1.5
96913	Follicular lymphoma, grade 2	14	2.8	11	3.4
97023	Mature T-cell lymphoma, NOS	14	2.8	10	3.1
97143	Anaplastic large cell lymphoma, T cell and Null cell type	12	2.4	7	2.1
97293	Precursor T-cell lymphoblastic lymphoma	12	2.4	1	0.3
	Others	85	16.9	53	16.3

Figure 3.4.2: Stage distribution of NHL among Saudi nationals, 2015





Figure 3.4.4: Comparison of ASR* for NHL among Saudi nationals with selected countries*



*ASR per 100,000

**Source for this information is summarized on page 56

Leukaemia (C91-C95)

Leukaemia ranked third among males and the sixth among females, there were 702 cases accounted to 5.8% of all cancer cases diagnosed among Saudi nationals in 2015. Leukaemia affected 408 (58.1%) males and 294 (41.9%) females with a male to female ratio of 138:100. The ASR was 4.5/100,000 for males and 3.4/100,000 for females. The median age at diagnosis was 25 years in males (ranged between 0 and 95 years) and 28.5 years in females (ranged between 0 and 94 years).

Figure 3.5.1: Age-Specific Incidence Rate (AIR) for leukaemia among Saudi nationals, 2015





Table 3.5.1: Morphological distribution of leukaemia among Saudi nationals, 2015

Code	Morphology	Male	%	Female	%
98363	Precursor B-cell lymphoblastic leukemia	101	24.8	72	24.5
98613	Acute myeloid leukemia, NOS	59	14.5	70	23.8
98633	Chronic myeloid leukemia, NOS	56	13.7	43	14.6
98233	B-cell chronic lymphocytic leukemia/small lymphocytic lymphom	40	9.8	23	7.8
98353	Precursor cell lymphoblastic leukemia, NOS	26	6.4	12	4.1
98373	Precursor T-cell lymphoblastic leukemia	22	5.4	3	1.0
98663	Acute promyelocytic leukemia, t(15;17)(q22;q11-12)	13	3.2	15	5.1
98003	Leukemia, NOS	11	2.7	5	1.7
98013	Acute leukemia, NOS	10	2.5	8	2.7
98263	Burkitt cell leukemia	9	2.2	3	1.0
	Others	61	15.0	40	13.6

Figure 3.5.3: Comparison of ASR* for leukaemia among Saudi nationals with selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56

Hodgkin's Lymphoma (C 81)

Hodgkin's lymphoma ranked the seventh among Saudi males and the eighth among Saudi females. There were 436 cases of Hodgkin's lymphoma accounted to 3.6% of all cancer cases diagnosed among Saudi nationals in 2015. Hodgkin's Lymphoma affected 267 (61.2%) males and 169 (38.8%) females, with a ration of male to female of 157:100. The ASR was 2.6/100,000 for males and 1.7/100,000 for females. The median age at diagnosis was 26 years (ranged between 3 and 84 years) in males and 26 years (ranged between 4 and 89) in females.

Figure 3.6.1: Age-Specific Incidence Rate (AIR) for Hodgkin's lymphoma among Saudi nationals, 2015.




Table 3.6.1: Morphological distribution of Hodgkin's Lymphoma among Saudi nationals, 2015

ICD-O-3	Morphology	Male	%	Female	%
96633	Hodgkin's lymphoma, nodular sclerosis, NOS	124	46.4	93	55.0
96503	Hodgkin's lymphoma, NOS	49	18.4	32	18.9
96523	Hodgkin's lymphoma, mixed cellularity, NOS	35	13.1	29	17.2
96593	Hodgkin's lymphoma, nodular lymphocyte predominance	31	11.6	10	5.9
96513	Hodgkin's lymphoma, lymphocyte-rich	13	4.9	2	1.2
96653	Hodgkin's lymphoma, nodular sclerosis, grade 1	4	1.5	0	0.0
96533	Hodgkin's lymphoma, lymphocyte depletion, NOS	3	1.1	1	0.6
96643	Hodgkin's lymphoma, nodular sclerosis, cellular phase	3	1.1	1	0.6
96673	Hodgkin's lymphoma, nodular sclerosis, grade 2	3	1.1	1	0.6
95903	Malignant lymphoma, NOS	1	0.4	0	0.0
97023	Mature T-cell lymphoma, NOS	1	0.4	0	0.0

Figure 3.6.2: Stage distribution of Hodgkin's lymphoma among Saudi nationals, 2015





Figure 3.6.4: Comparison of ASR* for Hodgkin's lymphoma among Saudi nationals with selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56

Lung Cancer (C33 - C34)

Lung cancer ranked fifth among Saudi males and fifteenth among Saudi females. There were 416 cases of lung cancer accounted to 3.5% of all newly diagnosed cases among Saudis in 2015. Lung cancer affected 324 (77.9%) males and 92 (22.1%) females with a male to female ratio of 352:100. The ASR was 4.8/100,000 for males and 1.3 /100,000 for females. The median age at diagnosis was 64 years in males (ranged between 4 and 94 years) and 63.5 years in females (ranged between 16 and 87 years).

Figure 3.7.1: Age-Specific Incidence Rate (AIR) for lung cancer among Saudi nationals, 2015




Table 3.7.1: Morphological distribution of lung cancer among Saudi nationals, 2015

ICD-O-3	Morphology	Male	%	Female	%
81403	Adenocarcinoma, NOS	111	34.3	39	42.4
80703	Squamous cell carcinoma, NOS	60	18.5	5	5.4
80413	Small cell carcinoma, NOS	34	10.5	7	7.6
80463	Non-small cell carcinoma	27	8.3	6	6.5
80103	Carcinoma, NOS	22	6.8	6	6.5
80013	Tumor cells, malignant	12	3.7	4	4.3
80713	Squamous cell carcinoma, keratinizing, NOS	7	2.2	1	1.1
82463	Neuroendocrine carcinoma, NOS	6	1.9	4	4.3
80003	Neoplasm, malignant	5	1.5	2	2.2
82603	Papillary adenocarcinoma, NOS	4	1.2	1	1.1
	Others	36	11.1	17	18.5

Figure 3.9.2: Stage distribution of liver cancer among Saudi nationals, 2015





Figure 3.7.4: Comparison of ASR* for lung cancer among Saudi nationals with selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56

Corpus uteri cancer (C54)

Corpus uteri cancer ranked the fourth among Saudi females with 403 cases accounted to 6.1 % of all cancer cases diagnosed among Saudi females in 2015. The ASR was 5.9/100,000 for Saudi female population. The median age at diagnosis was 61 years (Ranged between 22 and 99 years).

Figure 3.8.1: Age-Specific Incidence Rate (AIR) for corpus uteri cancer among Saudi females, 2015.




Table 3.8.1: Morphological distribution of corpus uteri cancer among Saudi females, 2015

ICD-O-3	Morphology	No.	%
8380	Endometrioid adenocarcinoma, NOS	257	63.8
8140	Adenocarcinoma, NOS	48	11.9
8010	Carcinoma, NOS	13	3.2
8441	Serous cystadenocarcinoma, NOS	13	3.2
8460	Papillary serous cystadenocarcinoma	12	3.0
8980	Carcinosarcoma, NOS	11	2.7
8480	Mucinous adenocarcinoma	5	1.2
8560	Adenosquamous carcinoma	4	1.0
8930	Endometrial stromal sarcoma, NOS	4	1.0
8890	Leiomyosarcoma, NOS	4	1.0
	Others	32	7.9

Figure 3.8.2: Stage distribution of corpus uteri cancer among Saudi females, 2015





Figure 3.8.4: Comparison of ASR* for corpus uteri cancer among Saudi females with selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56

Liver Cancer (C22)

Liver cancer ranked sixth among Saudi males and twelfth among Saudi females. There were 376 liver cancer cases accounted to 3.1% of all cancer cases diagnosed among Saudi nationals in 2015. Liver cancer affected 274 (72.9%) males and 102 (27.1%) females with a male to female ratio of 269:100. The ASR was 4.0/100,000 for males and 1.5/100,000 for females. The median age at diagnosis was 68 years in males (ranged between 0 and 99 years) and 64 years in females (ranged between 1 and 102 years).

Figure 3.9.1: Age-Specific Incidence Rate (AIR) for liver cancer among Saudi nationals, 2015




Table 3.9.1: Morphological distribution of liver cancer among Saudi nationals, 2015

Code	Morphology	Male	%	Female	%
81703	Hepatocellular carcinoma, NOS	204	74.5	78	76.5
81603	Cholangiocarcinoma	19	6.9	6	5.9
80013	Tumor cells, malignant	12	4.4	5	4.9
81723	Hepatocellular carcinoma, scirrhous	10	3.6	3	2.9
80103	Carcinoma, NOS	6	2.2	2	2.0
81403	Adenocarcinoma, NOS	6	2.2	4	3.9
89703	Hepatoblastoma	5	1.8	1	1.0
82403	Carcinoid tumor, NOS	2	0.7	0	0.0
82463	Neuroendocrine carcinoma, NOS	2	0.7	2	2.0
80003	Neoplasm, malignant	1	0.4	0	0.0
	Others	7	2.6	1	1.0

Figure 3.9.2: Stage distribution of liver cancer among Saudi nationals, 2015





Figure 3.9.4: Comparison of ASR* for liver cancer among Saudi nationals with selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56

Prostate Cancer (C61)

Prostate cancer ranked the Fourth among Saudi males with 340 cases accounted to 6.2% of all cancers cases diagnosed among Saudi males in 2015. The ASR was 5.4/100,000 for Saudi male population. The median age at diagnosis was 72 years (Ranged between 0 and 102 years).

Figure 3.10.1: Age-Specific Incidence Rate (AIR) for prostate cancers among Saudi nationals, 2015




Table 3.10.1: Morphological distribution of prostate cancers among Saudi nationals, 2015

ICD-O-3	Morphology	NO.	%
8140	Adenocarcinoma, NOS	304	89.4
8550	Acinar cell carcinoma	15	4.4
8010	Carcinoma, NOS	11	3.2
8000	Neoplasm, malignant	5	1.5
8001	Papillary adenocarcinoma, NOS	2	0.6
8260	Tumor cells, malignant	2	0.6
8900	Rhabdomyosarcoma, NOS	1	0.3

Figure 3.10.2: Stage distribution of prostate cancers among Saudi nationals, 2015





Figure 3.10.4: Comparison of ASR* for of prostate cancers among Saudi nationals with selected countries**



*ASR per 100,000

**Source for this information is summarized on page 56

References:

- 1 GLOBOCAN 2012, Cancer Incidence and Mortality Worldwide, IARC, Lyon: International agency for Research on Cancer. Available from: <http://globocan.iarc.fr/Pages/online.aspx>
- 2 Cancer Incidence among Nationals of the GCC States, 1998-2012
- 3 General Authority for statistics, Saudi Arabia



PART IV

CANCER INCIDENCE AMONG
NON-SAUDIS
2015

Cancer incidence among Non-Saudi population, 2015

Between January and December 2015, a total of 3,667 cancer cases were reported among the Non-Saudi population, 163 cases were excluded from analysis due to In-Situ and mismatch between ICD-O-3 and ICD-10 codes. Therefore, the total number of cases analyzed was 3,504. Out of this 1,816 (51.8 %) were males and 1,688 (48.2 %) were females. The ratio of male to female was 107:100. Taking into consideration the population structure of non-Saudis and the fact that cancer is primarily a disease of the elderly; the pattern of cancer had some significant differences. Those under 15 represented 15.2% of the population, and those aged 60 years and above represented 3.8% and the 15 to 59 age group represented 81% of Non-Saudi population. During 2015, approximately 2.9 % of all cancers occurred before the age of 15 years, 22.4 % occurred between the ages 15 to 39 years, 59.4% were between the ages 40-64 years, and 15.3 % occurred after the age of 64 years. The median age at diagnosis was 53 years in males (ranged between 0 and 100 years) and 47 years in females (ranged between 0 and 101).

Table 4.1: The ten most common cancers among Non-Saudi population, 2015

Site	All	%
Breast	718	20.5
Colorectal	392	11.2
Thyroid	223	6.4
NHL	192	5.5
Prostate	154	4.4
Lung	141	4.0
Leukemia	118	3.4
Stomach	116	3.3
Bladder	103	2.9
Kidney	94	2.7

Table 4.2: Distribution of Cancer Cases among Non-Saudi population, 2015

Nationality	Male	%	Female	%	Total	%
Yemen	348	19.2	261	15.5	609	17.4
Syrian Arab Republic	186	10.2	201	11.9	387	11.0
Egypt	195	10.7	190	11.3	385	11.0
Philippines	149	8.2	195	11.6	344	9.8
Sudan	165	9.1	155	9.2	320	9.1
Pakistan	127	7.0	80	4.7	207	5.9
India	95	5.2	48	2.8	143	4.1
Jordan	78	4.3	58	3.4	136	3.9
Gaza Strip(Palestine)	47	2.6	45	2.7	92	2.6
Bangladesh	67	3.7	9	0.5	76	2.2
Ethiopia	15	0.8	55	3.3	70	2.0
Eritrea	26	1.4	35	2.1	61	1.7
Indonesia	9	0.5	49	2.9	58	1.7
United States of America	44	2.4	8	0.5	52	1.5
United Kingdom	34	1.9	17	1.0	51	1.5
Lebanon	21	1.2	22	1.3	43	1.2
Bahrain	14	0.8	26	1.5	40	1.1
Myanmar	20	1.1	15	0.9	35	1.0
Nigeria	17	0.9	18	1.1	35	1.0
Non-Saudi, NOS	20	1.1	11	0.7	31	0.9
Afghanistan	15	0.8	15	0.9	30	0.9
Somalia	12	0.7	16	0.9	28	0.8
Morocco	6	0.3	20	1.2	26	0.7
Canada	16	0.9	5	0.3	21	0.6
Chad	7	0.4	14	0.8	21	0.6
Others Nationalities	83	4.6	120	7.1	203	5.8
Total	1816	100	1688	100	3504	100

Table 4.3: Most common cancers among Non-Saudi population by gender, 2015

Male	1816	%	Female	1688	%
Colorectal	287	15.8	Breast	698	41.4
Prostate	154	8.5	Thyroid	151	8.9
NHL	131	7.2	Colorectal	105	6.2
Lung	109	6.0	Corpus Uteri	81	4.8
Bladder	94	5.2	Ovary	63	3.7
Stomach	88	4.8	NHL	61	3.6
Leukemia	74	4.1	Cervix Uteri	47	2.8
Thyroid	72	4.0	Leukemia	44	2.6
Kidney	64	3.5	Lung	32	1.9
Hodgkin's Lymphoma	52	2.9	Kidney	30	1.8

Figure 4.1: Age-Specific Incidence Rate (AIR) for all cancers among Non-Saudi population, 2015





PART V

INCIDENCE TABLES

Table 5.1.1: Number Of Cases Among Saudi Males by Primary Site And Age Groups, 2015

ICD(10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	10	0	0	0	0	0	0	0	0	0	0	0	1	1	3	2	0	3	0.20%
C01-C02	Tongue	34	0	0	0	0	0	0	1	2	5	4	0	2	3	4	5	4	4	0.60%
C03-C06	Mouth	52	0	1	0	0	1	0	1	1	1	2	3	8	6	5	5	6	12	1.00%
C07-C08	Salivary glands	23	0	0	0	0	2	0	0	3	2	4	2	2	1	2	0	1	4	0.40%
C09	Tonsil	7	0	0	0	0	0	0	0	0	0	2	0	0	1	0	1	1	2	0.10%
C10	Other Oropharynx	3	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1	0.10%
C11	Nasopharynx	128	0	0	1	2	2	6	2	4	10	10	22	24	19	8	5	4	9	2.30%
C12-C13	Hypopharynx	5	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	2	0.10%
C14	Pharynx unspec.	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.00%
C15	Oesophagus	74	0	0	0	0	0	1	0	0	3	2	6	5	3	4	12	11	27	1.40%
C16	Stomach	185	0	1	0	0	2	2	4	5	4	10	9	16	18	15	21	24	54	3.40%
C17	Small intestine	37	0	0	0	0	0	0	2	0	4	3	3	2	4	5	4	2	8	0.70%
C18	Colon	475	0	0	1	0	1	1	3	15	16	26	35	60	76	55	57	45	84	8.70%
C19-C20	Rectum	335	0	0	1	0	0	3	4	3	13	27	29	36	57	45	27	41	49	6.10%
C21	Anus	17	0	0	0	0	0	0	0	1	0	1	2	2	3	2	1	3	2	0.30%
C22	Liver	274	0	5	1	2	1	1	2	3	4	6	10	19	33	32	38	33	84	5.00%
C23-C24	Gallbladder etc.	82	0	0	0	0	0	1	0	0	1	1	4	9	13	7	12	11	23	1.50%
C25	Pancreas	151	0	0	0	0	0	0	2	1	1	8	9	8	36	19	18	20	29	2.80%
C30-C31	Nose, sinuses etc.	17	0	0	0	0	1	0	0	2	1	0	1	2	2	1	3	0	4	0.30%
C32	Larynx	77	0	0	0	0	0	0	1	0	0	2	3	12	10	10	14	11	14	1.40%
C33-C34	Trachea,Bronchus,Lung	324	0	1	0	0	0	1	5	1	3	10	19	30	48	45	44	46	71	5.90%
C37-C38	Other Thoracic organs	20	0	0	0	0	1	2	2	2	1	2	0	3	0	0	1	3	3	0.40%
C40-C41	Bone	70	0	0	2	13	19	10	6	2	6	3	0	3	3	1	1	1	0	1.30%
C43	Melanoma of Skin	14	0	0	1	0	0	0	0	0	1	0	1	0	1	3	0	2	5	0.30%
C44	Other Skin	209	0	1	0	0	3	3	10	5	14	13	18	17	13	11	17	21	63	3.80%
C45	Mesothelioma	9	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	2	3	0.20%
C46	Kaposi sarcoma	28	0	1	0	0	0	0	0	0	0	2	1	3	3	1	3	4	10	0.50%
C47,C49	Connective,Soft tissue	87	0	7	3	4	3	10	4	13	5	6	5	7	7	3	2	2	6	1.60%
C50	Breast	37	0	0	0	0	0	0	0	0	2	7	8	3	5	1	2	4	5	0.70%
C60	Penis	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.00%
C61	Prostate	340	0	0	0	0	1	0	0	1	0	3	1	11	24	46	56	72	125	6.20%
C62	Testis	102	0	6	2	0	9	17	22	19	14	5	5	2	1	0	0	0	0	1.90%
C63	Other male genital	4	0	0	0	0	0	1	0	0	0	0	2	0	1	0	0	0	0	0.10%
C64	Kidney	199	0	13	5	1	0	3	6	12	8	7	19	19	30	19	21	16	20	3.60%
C65	Renal Pelvis	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0.10%
C66	Ureter	3	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0.10%
C67	Bladder	192	0	0	0	0	0	0	1	2	3	12	15	17	11	22	26	31	52	3.50%
C68	Other Urinary organs	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0.00%
C69	Eye	21	0	14	0	1	0	0	2	1	0	0	0	0	0	1	0	1	1	0.40%
C70-C72	Brain, Nervous system	194	0	22	19	10	9	13	8	9	12	10	12	13	22	11	12	6	6	3.60%
C73	Thyroid	227	0	0	1	2	4	12	10	23	37	26	25	18	20	17	9	5	18	4.20%
C74	Adrenal gland	15	0	12	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0.30%
C75	Other Endocrine	7	0	0	0	2	2	0	0	0	1	1	0	0	0	0	0	0	1	0.10%
C81	Hodgkin disease	267	0	3	17	21	42	42	28	28	18	14	12	13	4	9	3	7	6	4.90%
C82-C85,C96	Non-Hodgkin lymphoma	503	0	25	27	14	25	28	26	32	27	30	30	45	44	32	26	34	58	9.20%
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C90	Multiple Myeloma	55	0	0	0	0	0	2	0	1	3	5	4	7	5	7	7	4	10	1.00%
C91	Lymphoid Leukaemia	203	0	59	31	22	17	10	7	1	4	4	5	5	6	6	4	5	17	3.70%
C92-C94	Myeloid Leukaemia	182	0	11	3	14	8	15	22	18	9	13	8	11	10	8	13	7	12	3.30%
C95	Leukaemia unspec.	23	0	5	1	0	2	2	2	1	1	0	0	0	1	1	2	2	3	0.40%
Other	Other & unspecified	125	0	5	1	0	2	5	2	4	6	5	6	13	14	11	16	9	26	2.30%
All	All sites Total	5454	0	192	117	109	157	192	185	216	241	286	336	452	564	473	493	503	938	100.00%
Not C44	All sites but C44	5245	0	192	117	109	154	189	175	211	227	273	318	435	551	462	476	482	874	96.20%

Table 5.1.2: Number Of Cases Among Saudi Females by Primary Site And Age Groups, 2015

ICD(10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	3	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0.00%
C01-C02	Tongue	29	0	0	0	0	1	0	1	2	2	2	2	3	1	2	7	4	2	0.40%
C03-C06	Mouth	47	0	0	0	0	0	0	1	3	1	4	2	3	7	9	3	5	9	0.70%
C07-C08	Salivary glands	17	0	0	0	0	0	1	1	1	1	2	2	2	3	1	1	1	1	0.30%
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C10	Other Oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.00%
C11	Nasopharynx	46	0	0	0	0	4	4	1	2	7	0	7	6	3	2	3	2	5	0.70%
C12-C13	Hypopharynx	7	0	0	0	0	0	0	0	0	1	0	0	0	2	2	1	1	0	0.10%
C14	Pharynx unspec.	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.00%
C15	Oesophagus	56	0	0	0	0	0	0	0	1	2	3	0	4	3	9	4	8	22	0.90%
C16	Stomach	131	0	0	0	0	0	2	6	3	10	10	12	12	18	9	13	9	27	2.00%
C17	Small intestine	18	0	0	0	0	0	0	0	0	1	0	2	3	4	2	5	1	0	0.30%
C18	Colon	420	0	0	0	0	2	3	5	11	24	29	48	50	63	58	49	28	50	6.40%
C19-C20	Rectum	235	0	0	0	0	0	1	6	6	14	15	18	29	34	38	29	23	22	3.60%
C21	Anus	9	0	0	1	0	0	0	0	0	0	0	0	2	1	1	2	0	2	0.10%
C22	Liver	102	0	1	0	0	0	0	0	1	1	2	7	13	10	18	11	14	24	1.50%
C23-C24	Gallbladder etc.	87	0	0	0	0	0	0	1	2	3	2	10	7	12	9	16	12	13	1.30%
C25	Pancreas	95	0	0	0	0	0	0	2	1	3	5	10	10	16	12	17	10	9	1.40%
C30-C31	Nose, sinuses etc.	11	0	0	0	1	0	0	1	0	1	1	1	1	0	0	1	1	3	0.20%
C32	Larynx	16	0	0	0	0	0	0	0	2	0	0	0	2	3	3	1	2	3	0.20%
C33-C34	Trachea,Bronchus,Lung	92	0	0	0	0	1	3	2	1	1	3	6	8	12	11	9	18	17	1.40%
C37-C38	Other Thoracic organs	10	0	2	0	0	1	0	0	1	0	0	2	1	3	0	0	0	0	0.20%
C40-C41	Bone	48	0	3	5	9	7	2	3	4	1	2	2	1	2	1	2	2	2	0.70%
C43	Melanoma of Skin	15	0	0	1	0	0	0	0	0	0	2	2	1	1	0	1	3	4	0.20%
C44	Other Skin	138	0	0	1	2	1	3	5	2	8	5	8	6	16	12	12	18	39	2.10%
C45	Mesothelioma	4	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	1	0.10%
C46	Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.00%
C47;C49	Connective,Soft tissue	63	0	3	4	2	2	7	7	1	6	2	6	5	8	2	2	2	4	1.00%
C50	Breast	1979	0	0	0	1	3	11	38	127	176	264	356	334	212	161	105	90	101	30.10%
C51	Vulva	8	0	0	0	0	0	0	1	0	0	0	0	1	1	3	0	0	2	0.10%
C52	Vagina	10	0	1	0	1	0	0	0	0	0	2	0	2	1	0	2	0	1	0.20%
C53	Cervix Uteri	102	0	0	0	0	0	0	1	0	8	12	26	13	12	10	5	7	8	1.50%
C54	Corpus Uteri	403	0	0	0	0	0	3	4	7	14	14	29	50	62	75	55	43	47	6.10%
C55	Uterus unspec.	27	0	0	0	0	0	0	0	2	1	1	8	2	3	2	2	5	1	0.40%
C56	Ovary	220	0	1	1	10	7	7	10	19	14	18	16	22	15	17	21	18	24	3.30%
C57	Other Female Genital	9	0	0	0	0	0	1	1	0	0	0	2	2	1	0	0	2	0	0.10%
C58	Placenta	5	0	0	0	0	0	2	0	2	0	0	0	0	1	0	0	0	0	0.10%
C64	Kidney	116	0	19	4	1	0	1	0	2	6	6	15	11	16	10	10	10	5	1.80%
C65	Renal Pelvis	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0.00%
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C67	Bladder	47	0	0	0	0	0	0	1	0	2	1	2	9	5	8	4	4	11	0.70%
C68	Other Urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C69	Eye	17	0	11	0	0	1	1	0	0	0	0	1	0	0	0	0	1	2	0.30%
C70-C72	Brain, Nervous system	126	0	19	10	9	4	3	5	5	4	11	11	14	14	8	3	4	2	1.90%
C73	Thyroid	793	0	1	2	5	16	59	84	123	108	85	77	63	63	41	28	16	22	12.00%
C74	Adrenal gland	22	0	12	2	1	0	0	2	0	2	2	1	0	0	0	0	0	0	0.30%
C75	Other Endocrine	4	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	0	1	0.10%
C81	Hodgkin disease	169	0	1	7	17	22	28	24	15	9	6	6	8	6	10	1	4	5	2.60%
C82-C85;C96	Non-Hodgkin lymphoma	326	0	8	5	10	9	15	11	16	26	15	30	17	43	26	24	26	45	5.00%
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C90	Multiple Myeloma	50	0	0	0	0	0	1	3	0	3	2	4	4	6	3	8	10	6	0.80%
C91	Lymphoid Leukaemia	113	0	37	21	11	3	1	3	3	2	5	4	6	1	4	4	2	6	1.70%
C92-C94	Myeloid Leukaemia	168	0	14	10	10	5	6	25	13	11	9	12	12	10	11	5	7	8	2.60%
C95	Leukaemia unspec.	13	0	4	2	0	1	0	1	0	0	0	0	0	0	1	2	1	1	0.20%
Other	Other & unspecified	153	0	6	0	0	1	1	1	4	7	7	15	6	27	18	14	22	24	2.30%
All	All sites Total	6584	0	143	76	90	91	166	257	383	481	551	762	745	725	610	485	437	582	100.00%
Not C44	All sites but C44	6446	0	143	75	88	90	163	252	381	473	546	754	739	709	598	473	419	543	97.90%

Table 5.1.3: Age-Specific Incidence Rate (AIR), Age Standardised Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site and Age groups, 2015

ICD(10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	10	0	0	0	0	0	0	0	0	0	0	0	0.2	0.3	1.2	1.4	0	2	0.1	0.2
C01-C02	Tongue	34	0	0	0	0	0	0	0.1	0.2	0.7	0.6	0	0.5	0.9	1.7	3.4	3.7	2.6	0.3	0.5
C03-C06	Mouth	52	0	0.1	0	0	0.1	0	0.1	0.1	0.1	0.3	0.6	1.9	1.8	2.1	3.4	5.6	7.9	0.5	0.7
C07-C08	Salivary glands	23	0	0	0	0	0.2	0	0	0.3	0.3	0.6	0.4	0.5	0.3	0.8	0	0.9	2.6	0.2	0.3
C09	Tonsil	7	0	0	0	0	0	0	0	0	0	0.3	0	0	0.3	0	0.7	0.9	1.3	0.1	0.1
C10	Other Oropharynx	3	0	0	0	0	0	0	0	0	0	0	0	0.5	0	0	0	0	0.7	0	0
C11	Nasopharynx	128	0	0	0.1	0.2	0.2	0.6	0.2	0.5	1.3	1.6	4.1	5.6	5.7	3.3	3.4	3.7	6	1.3	1.5
C12-C13	Hypopharynx	5	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0.7	0.9	1.3	0	0.1
C14	Pharynx unspec.	1	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0
C15	Oesophagus	74	0	0	0	0	0	0.1	0	0	0.4	0.3	1.1	1.2	0.9	1.7	8.2	10.3	17.9	0.7	1.1
C16	Stomach	185	0	0.1	0	0	0.2	0.2	0.4	0.6	0.5	1.6	1.7	3.8	5.4	6.2	14.3	22.4	35.8	1.8	2.6
C17	Small intestine	37	0	0	0	0	0	0	0.2	0	0.5	0.5	0.6	0.5	1.2	2.1	2.7	1.9	5.3	0.4	0.5
C18	Colon	475	0	0	0.1	0	0.1	0.1	0.3	1.7	2.1	4.1	6.5	14.1	22.9	22.8	38.9	42.1	55.6	4.7	6.6
C19-C20	Rectum	335	0	0	0.1	0	0	0.3	0.4	0.3	1.7	4.2	5.4	8.4	17.2	18.7	18.4	38.3	32.5	3.3	4.6
C21	Anus	17	0	0	0	0	0	0	0	0.1	0	0.2	0.4	0.5	0.9	0.8	0.7	2.8	1.3	0.2	0.2
C22	Liver	274	0	0.5	0.1	0.2	0.1	0.1	0.2	0.3	0.5	0.9	1.9	4.5	9.9	13.3	25.9	30.9	55.6	2.7	4
C23-C24	Gallbladder etc.	82	0	0	0	0	0	0.1	0	0	0.1	0.2	0.7	2.1	3.9	2.9	8.2	10.3	15.2	0.8	1.2
C25	Pancreas	151	0	0	0	0	0	0	0.2	0.1	0.1	1.3	1.7	1.9	10.8	7.9	12.3	18.7	19.2	1.5	2.2
C30-C31	Nose, sinuses etc.	17	0	0	0	0	0.1	0	0	0.2	0.1	0	0.2	0.5	0.6	0.4	2	0	2.6	0.2	0.2
C32	Larynx	77	0	0	0	0	0	0	0.1	0	0	0.3	0.6	2.8	3	4.2	9.6	10.3	9.3	0.8	1.2
C33-C34	Trachea,Bronchus,Lung	324	0	0.1	0	0	0	0.1	0.5	0.1	0.4	1.6	3.6	7	14.4	18.7	30	43	47	3.2	4.8
C37-C38	Other Thoracic organs	20	0	0	0	0	0.1	0.2	0.2	0.2	0.1	0.3	0	0.7	0	0	0.7	2.8	2	0.2	0.2
C40-C41	Bone	70	0	0	0.2	1.4	2.1	1	0.6	0.2	0.8	0.5	0	0.7	0.9	0.4	0.7	0.9	0	0.7	0.7
C43	Melanoma of Skin	14	0	0	0.1	0	0	0	0	0	0.1	0	0.2	0	0.3	1.2	0	1.9	3.3	0.1	0.2
C44	Other Skin	209	0	0.1	0	0	0.3	0.3	1.1	0.6	1.9	2	3.4	4	3.9	4.6	11.6	19.6	41.7	2.1	2.7
C45	Mesothelioma	9	0	0	0	0	0	0	0	0	0	0	0	0.2	0.6	0	0.7	1.9	2	0.1	0.1
C46	Kaposi sarcoma	28	0	0.1	0	0	0	0	0	0	0	0.3	0.2	0.7	0.9	0.4	2	3.7	6.6	0.3	0.4
C47;C49	Connective,Soft tissue	87	0	0.7	0.3	0.4	0.3	1	0.4	1.5	0.7	0.9	0.9	1.6	2.1	1.2	1.4	1.9	4	0.9	0.9
C50	Breast	37	0	0	0	0	0	0	0	0	0.3	1.1	1.5	0.7	1.5	0.4	1.4	3.7	3.3	0.4	0.5
C60	Penis	1	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0
C61	Prostate	340	0	0	0	0	0.1	0	0	0.1	0	0.5	0.2	2.6	7.2	19.1	38.2	67.3	82.8	3.4	5.4
C62	Testis	102	0	0.6	0.2	0	1	1.7	2.3	2.2	1.9	0.8	0.9	0.5	0.3	0	0	0	0	1	0.9
C63	Other male genital	4	0	0	0	0	0	0.1	0	0	0	0	0.4	0	0.3	0	0	0	0	0	0
C64	Kidney	199	0	1.2	0.5	0.1	0	0.3	0.6	1.4	1.1	1.1	3.6	4.5	9	7.9	14.3	15	13.2	2	2.6
C65	Renal Pelvis	4	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0.7	0	1.3	0	0.1
C66	Ureter	3	0	0	0	0	0	0	0	0	0	0	0.2	0	0.3	0	0	0.9	0	0	0
C67	Bladder	192	0	0	0	0	0	0	0.1	0.2	0.4	1.9	2.8	4	3.3	9.1	17.7	29	34.4	1.9	2.8
C68	Other Urinary organs	2	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0.4	0	0	0	0	0
C69	Eye	21	0	1.3	0	0.1	0	0	0.2	0.1	0	0	0	0	0	0.4	0	0.9	0.7	0.2	0.2
C70-C72	Brain, Nervous system	194	0	2	1.8	1.1	1	1.3	0.8	1	1.6	1.6	2.2	3	6.6	4.6	8.2	5.6	4	1.9	2.2
C73	Thyroid	227	0	0	0.1	0.2	0.5	1.2	1.1	2.7	4.9	4.1	4.7	4.2	6	7.1	6.1	4.7	11.9	2.2	2.5
C74	Adrenal gland	15	0	1.1	0	0.1	0	0.1	0	0.1	0	0	0	0	0	0	0	0	0	0.1	0.2
C75	Other Endocrine	7	0	0	0	0.2	0.2	0	0	0	0.1	0.2	0	0	0	0	0	0	0.7	0.1	0.1
C81	Hodgkin disease	267	0	0.3	1.6	2.2	4.7	4.1	2.9	3.3	2.4	2.2	2.2	3	1.2	3.7	2	6.5	4	2.6	2.6
C82-C85;C96	Non-Hodgkin lymphoma	503	0	2.3	2.6	1.5	2.8	2.7	2.7	3.7	3.6	4.7	5.6	10.5	13.2	13.3	17.7	31.8	38.4	5	5.9
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	55	0	0	0	0	0	0.2	0	0.1	0.4	0.8	0.7	1.6	1.5	2.9	4.8	3.7	6.6	0.5	0.7
C91	Lymphoid Leukaemia	203	0	5.5	2.9	2.3	1.9	1	0.7	0.1	0.5	0.6	0.9	1.2	1.8	2.5	2.7	4.7	11.3	2	2.2
C92-C94	Myeloid Leukaemia	182	0	1	0.3	1.5	0.9	1.5	2.3	2.1	1.2	2	1.5	2.6	3	3.3	8.9	6.5	7.9	1.8	2
C95	Leukaemia unspec.	23	0	0.5	0.1	0	0.2	0.2	0.2	0.1	0.1	0	0	0	0.3	0.4	1.4	1.9	2	0.2	0.3
Other	Other & unspecified	125	0	0.5	0.1	0	0.2	0.5	0.2	0.5	0.8	0.8	1.1	3	4.2	4.6	10.9	8.4	17.2	1.2	1.7
All	All sites Total	5454	0	18	11	12	18	19	19	25	32	45	63	106	170	196	336	470	621	53.9	70.7
Not C44	All sites but C44	5245	0	18	11	12	17	18	18	25	30	43	59	102	166	192	325	451	580	51.9	68

Table 5.1.4: Age-Spesific Incidence Rate (AIR), Age Standardised Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site and Age groups, 2015

ICD(10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	3	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0.6	0	0.6	0	0
C01-C02	Tongue	29	0	0	0	0	0.1	0	0.1	0.2	0.3	0.3	0.4	0.7	0.3	0.9	4.5	3.7	1.3	0.3	0.4
C03-C06	Mouth	47	0	0	0	0	0	0	0.1	0.4	0.1	0.7	0.4	0.7	2.3	4	1.9	4.6	5.7	0.5	0.7
C07-C08	Salivary glands	17	0	0	0	0	0	0.1	0.1	0.1	0.1	0.3	0.4	0.5	1	0.4	0.6	0.9	0.6	0.2	0.2
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C10	Other Oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.6	0	0	0	0
C11	Nasopharynx	46	0	0	0	0	0.5	0.4	0.1	0.2	1	0	1.4	1.5	1	0.9	1.9	1.8	3.1	0.5	0.5
C12-C13	Hypopharynx	7	0	0	0	0	0	0	0	0	0.1	0	0	0	0.7	0.9	0.6	0.9	0	0.1	0.1
C14	Pharynx unspec.	1	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0
C15	Oesophagus	56	0	0	0	0	0	0	0	0.1	0.3	0.5	0	1	1	4	2.6	7.3	13.8	0.6	0.8
C16	Stomach	131	0	0	0	0	0	0.2	0.6	0.4	1.4	1.6	2.4	3	5.9	4	8.4	8.2	17	1.3	1.7
C17	Small intestine	18	0	0	0	0	0	0	0	0	0.1	0	0.4	0.7	1.3	0.9	3.2	0.9	0	0.2	0.3
C18	Colon	420	0	0	0	0	0.2	0.3	0.5	1.3	3.3	4.7	9.5	12.4	20.6	25.7	31.7	25.6	31.4	4.3	5.8
C19-C20	Rectum	235	0	0	0	0	0	0.1	0.6	0.7	1.9	2.4	3.6	7.2	11.1	16.9	18.7	21	13.8	2.4	3.3
C21	Anus	9	0	0	0.1	0	0	0	0	0	0	0	0	0.5	0.3	0.4	1.3	0	1.3	0.1	0.1
C22	Liver	102	0	0.1	0	0	0	0	0	0.1	0.1	0.3	1.4	3.2	3.3	8	7.1	12.8	15.1	1	1.5
C23-C24	Gallbladder etc.	87	0	0	0	0	0	0	0.1	0.2	0.4	0.3	2	1.7	3.9	4	10.3	11	8.2	0.9	1.3
C25	Pancreas	95	0	0	0	0	0	0	0.2	0.1	0.4	0.8	2	2.5	5.2	5.3	11	9.1	5.7	1	1.4
C30-C31	Nose, sinuses etc.	11	0	0	0	0.1	0	0	0.1	0	0.1	0.2	0.2	0.2	0	0	0.6	0.9	1.9	0.1	0.1
C32	Larynx	16	0	0	0	0	0	0	0	0.2	0	0	0	0.5	1	1.3	0.6	1.8	1.9	0.2	0.2
C33-C34	Trachea,Bronchus,Lung	92	0	0	0	0	0.1	0.3	0.2	0.1	0.1	0.5	1.2	2	3.9	4.9	5.8	16.4	10.7	0.9	1.3
C37-C38	Other Thoracic organs	10	0	0.2	0	0	0.1	0	0	0.1	0	0	0.4	0.2	1	0	0	0	0	0.1	0.1
C40-C41	Bone	48	0	0.3	0.5	1	0.8	0.2	0.3	0.5	0.1	0.3	0.4	0.2	0.7	0.4	1.3	1.8	1.3	0.5	0.5
C43	Melanoma of Skin	15	0	0	0.1	0	0	0	0	0	0	0.3	0.4	0.2	0.3	0	0.6	2.7	2.5	0.2	0.2
C44	Other Skin	138	0	0	0.1	0.2	0.1	0.3	0.5	0.2	1.1	0.8	1.6	1.5	5.2	5.3	7.8	16.4	24.5	1.4	1.9
C45	Mesothelioma	4	0	0	0	0	0	0	0	0	0	0	0	0	0.7	0.4	0	0	0.6	0	0.1
C46	Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.9	0	0	0
C47;C49	Connective,Soft tissue	63	0	0.3	0.4	0.2	0.2	0.7	0.8	0.1	0.8	0.3	1.2	1.2	2.6	0.9	1.3	1.8	2.5	0.6	0.7
C50	Breast	1979	0	0	0	0.1	0.4	1.2	4.1	15.1	24	43.1	70.4	82.9	69.4	71.5	67.9	82.2	63.4	20.3	24.3
C51	Vulva	8	0	0	0	0	0	0	0.1	0	0	0	0	0.2	0.3	1.3	0	0	1.3	0.1	0.1
C52	Vagina	10	0	0.1	0	0.1	0	0	0	0	0	0.3	0	0.5	0.3	0	1.3	0	0.6	0.1	0.1
C53	Cervix Uteri	102	0	0	0	0	0	0	0.1	0	1.1	2	5.1	3.2	3.9	4.4	3.2	6.4	5	1	1.3
C54	Corpus Uteri	403	0	0	0	0	0	0.3	0.4	0.8	1.9	2.3	5.7	12.4	20.3	33.3	35.5	39.3	29.5	4.1	5.9
C55	Uterus unspec.	27	0	0	0	0	0	0	0	0.2	0.1	0.2	1.6	0.5	1	0.9	1.3	4.6	0.6	0.3	0.4
C56	Ovary	220	0	0.1	0.1	1.1	0.8	0.7	1.1	2.3	1.9	2.9	3.2	5.5	4.9	7.5	13.6	16.4	15.1	2.3	2.8
C57	Other Female Genital	9	0	0	0	0	0	0.1	0.1	0	0	0	0.4	0.5	0.3	0	0	1.8	0	0.1	0.1
C58	Placenta	5	0	0	0	0	0	0.2	0	0.2	0	0	0	0	0.3	0	0	0	0	0.1	0
C64	Kidney	116	0	1.8	0.4	0.1	0	0.1	0	0.2	0.8	1	3	2.7	5.2	4.4	6.5	9.1	3.1	1.2	1.5
C65	Renal Pelvis	2	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0.6	0	0	0	0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C67	Bladder	47	0	0	0	0	0	0	0.1	0	0.3	0.2	0.4	2.2	1.6	3.6	2.6	3.7	6.9	0.5	0.7
C68	Other Urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	17	0	1.1	0	0	0.1	0.1	0	0	0	0	0.2	0	0	0	0	0.9	1.3	0.2	0.2
C70-C72	Brain, Nervous system	126	0	1.8	1	1	0.5	0.3	0.5	0.6	0.5	1.8	2.2	3.5	4.6	3.6	1.9	3.7	1.3	1.3	1.5
C73	Thyroid	793	0	0.1	0.2	0.5	1.9	6.3	9	14.6	14.7	13.9	15.2	15.6	20.6	18.2	18.1	14.6	13.8	8.1	8.4
C74	Adrenal gland	22	0	1.2	0.2	0.1	0	0	0.2	0	0.3	0.3	0.2	0	0	0	0	0	0	0.2	0.2
C75	Other Endocrine	4	0	0	0	0	0	0	0	0.1	0	0.2	0	0	0.3	0	0	0	0.6	0	0
C81	Hodgkin disease	169	0	0.1	0.7	1.9	2.6	3	2.6	1.8	1.2	1	1.2	2	2	4.4	0.6	3.7	3.1	1.7	1.7
C82-C85;C96	Non-Hodgkin lymphoma	326	0	0.8	0.5	1.1	1.1	1.6	1.2	1.9	3.5	2.4	5.9	4.2	14.1	11.5	15.5	23.8	28.3	3.3	4.1
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	50	0	0	0	0	0	0.1	0.3	0	0.4	0.3	0.8	1	2	1.3	5.2	9.1	3.8	0.5	0.7
C91	Lymphoid Leukaemia	113	0	3.6	2.1	1.2	0.4	0.1	0.3	0.4	0.3	0.8	0.8	1.5	0.3	1.8	2.6	1.8	3.8	1.2	1.3
C92-C94	Myeloid Leukaemia	168	0	1.3	1	1.1	0.6	0.6	2.7	1.5	1.5	1.5	2.4	3	3.3	4.9	3.2	6.4	5	1.7	1.9
C95	Leukaemia unspec.	13	0	0.4	0.2	0	0.1	0	0.1	0	0	0	0	0	0	0.4	1.3	0.9	0.6	0.1	0.2
Other	Other & unspecified	153	0	0.6	0	0	0.1	0.1	0.1	0.5	1	1.1	3	1.5	8.8	8	9	20.1	15.1	1.6	2.2
All	All sites Total	6584	0	14	7	10	11	18	28	46	66	90	151	185	237	271	313	399	365	67.6	83.3
Not C44	All sites but C44	6446	0	14	7	10	11	17	27	45	65	89	149	183	232	265	306	383	341	66.2	81.4

Table 5.4.1: Number Of Cases Among Non-Saudi Males by Primary Site And Age Groups, 2015

ICD (10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.10%
C01-C02	Tongue	36	0	0	0	0	0	1	1	4	5	5	6	5	5	1	2	1	0	2.00%
C03-C06	Mouth	21	0	1	0	0	0	1	5	2	2	3	3	0	0	1	2	1	0	1.20%
C07-C08	Salivary glands	8	0	0	0	0	1	0	0	2	1	1	0	2	0	0	1	0	0	0.40%
C09	Tonsil	2	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0.10%
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C11	Nasopharynx	32	0	0	0	1	0	0	1	6	4	2	9	3	2	2	1	1	0	1.80%
C12-C13	Hypopharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0.10%
C14	Pharynx unspec.	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.10%
C15	Oesophagus	23	0	0	0	0	1	0	1	1	1	1	2	4	5	3	1	3	0	1.30%
C16	Stomach	88	0	0	0	0	0	1	3	6	7	8	9	14	15	10	5	3	7	4.80%
C17	Small intestine	16	0	0	0	0	0	0	1	0	0	1	1	6	0	2	3	0	2	0.90%
C18	Colon	172	0	0	0	0	1	1	9	8	13	11	18	21	28	29	19	10	4	9.50%
C19-C20	Rectum	115	0	0	0	0	0	0	9	7	4	13	14	18	16	16	6	7	5	6.30%
C21	Anus	11	0	0	0	0	0	1	0	0	2	2	1	1	3	0	1	0	0	0.60%
C22	Liver	30	0	0	0	1	1	1	1	0	0	2	4	4	5	3	3	1	4	1.70%
C23-C24	Gallbladder etc.	17	0	0	0	0	0	0	0	0	2	1	0	2	6	3	3	0	0	0.90%
C25	Pancreas	28	0	0	0	0	0	0	0	3	4	1	0	3	3	6	5	1	2	1.50%
C30-C31	Nose, sinuses etc.	10	0	0	0	0	0	0	1	0	2	2	0	1	0	2	1	0	1	0.60%
C32	Larynx	23	0	0	0	0	0	0	0	0	2	0	3	7	7	1	2	1	0	1.30%
C33-C34	Trachea,Bronchus,Lung	109	0	0	0	0	0	0	1	4	3	6	13	15	25	13	18	6	5	6.00%
C37-C38	Other Thoracic organs	11	0	0	0	0	0	0	0	1	2	0	0	2	2	3	0	1	0	0.60%
C40-C41	Bone	23	0	1	2	0	1	4	2	1	1	6	0	1	2	2	0	0	0	1.30%
C43	Melanoma of Skin	12	0	0	0	0	0	0	0	1	1	2	2	1	4	0	1	0	0	0.70%
C44	Other Skin	137	0	0	1	0	1	1	3	4	9	9	15	18	27	20	15	7	7	7.50%
C45	Mesothelioma	4	0	0	0	0	0	0	0	1	1	0	0	2	0	0	0	0	0	0.20%
C46	Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C47,C49	Connective,Soft tissue	35	0	5	1	0	0	1	2	2	1	6	2	3	3	4	2	2	1	1.90%
C50	Breast	20	0	0	0	0	0	0	0	1	2	3	2	4	2	2	3	1	0	1.10%
C60	Penis	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.10%
C61	Prostate	154	0	0	0	0	0	0	0	0	0	2	0	17	22	37	27	19	30	8.50%
C62	Testis	34	0	0	1	0	0	4	12	9	2	4	0	0	2	0	0	0	0	1.90%
C63	Other male genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C64	Kidney	64	0	1	0	0	0	1	2	0	6	5	9	7	15	8	3	2	5	3.50%
C65	Renal Pelvis	3	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0.20%
C66	Ureter	3	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0.20%
C67	Bladder	94	0	1	0	0	0	0	1	1	2	8	6	10	23	16	12	8	6	5.20%
C68	Other Urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C69	Eye	5	0	3	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0.30%
C70-C72	Brain, Nervous system	51	0	2	1	0	1	1	5	3	7	4	3	8	9	3	3	1	0	2.80%
C73	Thyroid	72	0	0	1	0	0	3	4	8	6	8	14	14	3	9	2	0	0	4.00%
C74	Adrenal gland	4	0	1	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	0.20%
C75	Other Endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C81	Hodgkin disease	52	0	0	0	1	3	2	9	7	8	5	5	5	5	1	1	0	0	2.90%
C82-C85,C96	Non-Hodgkin lymphoma	131	0	1	4	3	2	6	7	7	12	10	16	17	20	13	4	3	6	7.20%
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C90	Multiple Myeloma	16	0	0	0	0	0	0	1	0	2	1	1	3	2	3	3	0	0	0.90%
C91	Lymphoid Leukaemia	28	0	8	6	1	1	1	1	1	0	1	3	0	2	1	0	1	1	1.50%
C92-C94	Myeloid Leukaemia	45	0	3	3	1	1	3	4	0	4	3	6	5	5	3	1	1	2	2.50%
C95	Leukaemia unspec.	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0.10%
Other	Other & unspecified	71	0	1	0	0	1	2	5	3	4	6	5	9	13	13	5	1	3	3.90%
All	All sites Total	1816	0	28	20	8	17	35	92	94	122	143	176	236	283	231	157	82	92	100.00%
Not C44	All sites but C44	1679	0	28	19	8	16	34	89	90	113	134	161	218	256	211	142	75	85	92.50%

Table 5.4.2: Number Of Cases Among Non-Saudi Females by Primary Site And Age Groups, 2015

ICD(10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.10%
C01-C02	Tongue	10	0	0	0	0	0	0	0	0	0	1	1	2	2	1	2	0	1	0.60%
C03-C06	Mouth	4	0	0	0	0	0	0	0	0	0	0	2	0	0	0	1	1	0	0.20%
C07-C08	Salivary glands	4	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0.20%
C09	Tonsil	2	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0.10%
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C11	Nasopharynx	16	0	1	0	0	0	2	2	2	2	3	2	1	1	0	0	0	0	0.90%
C12-C13	Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C14	Pharynx unspec.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C15	Oesophagus	11	0	0	0	0	0	0	0	0	2	0	2	1	1	3	1	0	1	0.70%
C16	Stomach	28	0	0	0	0	0	0	1	2	3	0	2	2	2	5	3	5	3	1.70%
C17	Small intestine	8	0	0	0	0	0	0	1	1	0	1	3	1	0	1	0	0	0	0.50%
C18	Colon	73	0	0	0	0	1	0	5	4	9	8	8	12	11	9	2	3	1	4.30%
C19-C20	Rectum	32	0	0	0	0	0	0	0	3	4	4	3	4	4	4	5	0	1	1.90%
C21	Anus	7	0	0	0	0	0	0	1	1	0	0	1	0	2	1	1	0	0	0.40%
C22	Liver	14	0	1	0	0	0	0	0	0	0	0	2	2	0	4	0	2	3	0.80%
C23-C24	Gallbladder etc.	14	0	0	0	0	0	0	0	0	0	0	3	1	3	3	2	2	0	0.80%
C25	Pancreas	23	0	1	0	0	0	0	0	1	2	2	2	2	3	2	3	3	2	1.40%
C30-C31	Nose, sinuses etc.	4	0	0	0	0	0	0	1	0	0	1	0	1	0	0	1	0	0	0.20%
C32	Larynx	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.10%
C33-C34	Trachea,Bronchus,Lung	32	0	0	0	0	1	1	1	2	0	4	1	4	6	4	2	3	3	1.90%
C37-C38	Other Thoracic organs	2	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0.10%
C40-C41	Bone	12	0	0	1	2	0	1	3	2	1	0	0	1	0	0	0	0	1	0.70%
C43	Melanoma of Skin	6	0	0	0	0	0	0	0	0	1	1	1	1	1	0	0	0	1	0.40%
C44	Other Skin	41	0	0	0	1	2	0	1	3	2	2	4	6	9	1	4	3	3	2.40%
C45	Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C46	Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C47-C49	Connective,Soft tissue	21	0	0	0	2	1	3	2	1	1	5	1	4	0	0	1	0	0	1.20%
C50	Breast	698	0	0	0	0	0	4	26	42	90	124	117	107	81	49	32	13	13	41.40%
C51	Vulva	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0.10%
C52	Vagina	4	0	0	0	0	0	0	0	0	0	2	0	1	1	0	0	0	0	0.20%
C53	Cervix Uteri	47	0	0	0	0	0	0	2	0	6	4	10	8	9	4	1	1	2	2.80%
C54	Corpus Uteri	81	0	0	0	0	0	1	0	0	7	9	12	12	12	11	10	3	4	4.80%
C55	Uterus unspec.	14	0	0	0	0	0	0	0	0	0	1	2	3	3	2	1	1	1	0.80%
C56	Ovary	63	0	0	1	1	1	1	5	6	2	8	8	6	6	3	5	5	5	3.70%
C57	Other Female Genital	3	0	0	0	0	0	0	0	2	0	0	0	0	1	0	0	0	0	0.20%
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C64	Kidney	30	0	2	2	1	1	2	0	2	1	2	6	4	2	3	0	1	1	1.80%
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C67	Bladder	9	0	0	0	0	0	0	0	0	0	0	0	1	1	3	1	0	3	0.50%
C68	Other Urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C69	Eye	5	0	2	0	0	0	1	1	0	0	0	0	0	0	0	0	0	1	0.30%
C70-C72	Brain, Nervous system	29	0	6	1	0	1	1	1	3	3	3	3	2	1	3	0	1	0	1.70%
C73	Thyroid	151	0	2	0	0	2	3	17	24	28	25	18	18	6	6	1	0	1	8.90%
C74	Adrenal gland	3	0	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.20%
C75	Other Endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C81	Hodgkin disease	28	0	0	0	0	5	3	7	4	1	3	1	1	1	0	2	0	0	1.70%
C82-C85;C96	Non-Hodgkin lymphoma	61	0	0	1	2	4	1	3	1	8	4	7	7	6	6	2	3	6	3.60%
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C90	Multiple Myeloma	12	0	0	0	0	0	0	0	0	2	0	0	3	2	1	1	0	3	0.70%
C91	Lymphoid Leukaemia	21	0	8	4	1	0	0	2	0	1	1	0	1	2	0	0	1	0	1.20%
C92-C94	Myeloid Leukaemia	15	0	0	0	0	2	0	0	1	2	2	4	0	2	2	0	0	0	0.90%
C95	Leukaemia unspec.	8	0	0	1	0	0	0	1	1	1	1	0	1	0	0	0	1	1	0.50%
Other	Other & unspecified	38	0	0	0	0	1	0	0	2	5	5	7	4	5	3	2	4	0	2.30%
All	All sites Total	1688	0	25	11	10	22	24	83	110	185	228	235	226	187	136	88	57	61	100.00%
Not C44	All sites but C44	1647	0	25	11	9	20	24	82	107	183	226	231	220	178	135	84	54	58	97.60%

Table 5.4.3: Age-Spesific Incidence Rate (AIR), Age Standardised Incidence Rate (ASR) Among Non-Saudi Males (per 100,000) by Primary Site and Age groups, 2015

ICD(10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	1	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0
C01-C02	Tongue	36	0	0	0	0	0	0.4	0.1	0.5	0.4	0.4	0.7	0.8	1.4	0.5	2.9	3.2	0	0.5	0.4
C03-C06	Mouth	21	0	0.4	0	0	0	0.4	0.7	0.2	0.2	0.2	0.3	0	0	0.5	2.9	3.2	0	0.3	0.4
C07-C08	Salivary glands	8	0	0	0	0	0.4	0	0	0.2	0.1	0.1	0	0.3	0	0	1.5	0	0	0.1	0.1
C09	Tonsil	2	0	0	0	0	0	0	0	0	0	0	0.1	0.2	0	0	0	0	0	0	0
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C11	Nasopharynx	32	0	0	0	0.4	0	0	0.1	0.7	0.3	0.2	1	0.5	0.5	1	1.5	3.2	0	0.4	0.4
C12-C13	Hypopharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	1.5	0	0	0	0.1
C14	Pharynx unspec.	1	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0
C15	Oesophagus	23	0	0	0	0	0.4	0	0.1	0.1	0.1	0.1	0.2	0.6	1.4	1.5	1.5	9.5	0	0.3	0.5
C16	Stomach	88	0	0	0	0	0	0.4	0.4	0.7	0.5	0.6	1	2.3	4.1	5.1	7.3	9.5	26.6	1.1	1.7
C17	Small intestine	16	0	0	0	0	0	0	0.1	0	0	0.1	0.1	1	0	1	4.4	0	7.6	0.2	0.4
C18	Colon	172	0	0	0	0	0.4	0.4	1.3	0.9	1	0.9	2	3.4	7.6	14.7	27.7	31.8	15.2	2.2	3.3
C19-C20	Rectum	115	0	0	0	0	0	0	1.3	0.8	0.3	1.1	1.5	2.9	4.3	8.1	8.7	22.3	19	1.5	2.1
C21	Anus	11	0	0	0	0	0	0.4	0	0	0.2	0.2	0.1	0.2	0.8	0	1.5	0	0	0.1	0.1
C22	Liver	30	0	0	0	0.4	0.4	0.4	0.1	0	0	0.2	0.4	0.6	1.4	1.5	4.4	3.2	15.2	0.4	0.8
C23-C24	Gallbladder etc.	17	0	0	0	0	0	0	0	0	0.2	0.1	0	0.3	1.6	1.5	4.4	0	0	0.2	0.3
C25	Pancreas	28	0	0	0	0	0	0	0	0.3	0.3	0.1	0	0.5	0.8	3	7.3	3.2	7.6	0.4	0.7
C30-C31	Nose, sinuses etc.	10	0	0	0	0	0	0	0.1	0	0.2	0.2	0	0.2	0	1	1.5	0	3.8	0.1	0.2
C32	Larynx	23	0	0	0	0	0	0	0	0	0.2	0	0.3	1.1	1.9	0.5	2.9	3.2	0	0.3	0.3
C33-C34	Trachea,Bronchus,Lung	109	0	0	0	0	0	0	0.1	0.5	0.2	0.5	1.4	2.4	6.8	6.6	26.2	19.1	19	1.4	2.4
C37-C38	Other Thoracic organs	11	0	0	0	0	0	0	0	0.1	0.2	0	0	0.3	0.5	1.5	0	3.2	0	0.1	0.2
C40-C41	Bone	23	0	0.4	0.6	0	0.4	1.5	0.3	0.1	0.1	0.5	0	0.2	0.5	1	0	0	0	0.3	0.4
C43	Melanoma of Skin	12	0	0	0	0	0	0	0	0.1	0.1	0.2	0.2	0.2	1.1	0	1.5	0	0	0.2	0.1
C44	Other Skin	137	0	0	0.3	0	0.4	0.4	0.4	0.5	0.7	0.7	1.7	2.9	7.3	10.1	21.8	22.3	26.6	1.8	2.8
C45	Mesothelioma	4	0	0	0	0	0	0	0	0.1	0.1	0	0	0.3	0	0	0	0	0	0.1	0
C46	Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C47;C49	Connective,Soft tissue	35	0	1.9	0.3	0	0	0.4	0.3	0.2	0.1	0.5	0.2	0.5	0.8	2	2.9	6.4	3.8	0.5	0.8
C50	Breast	20	0	0	0	0	0	0	0	0.1	0.2	0.2	0.2	0.6	0.5	1	4.4	3.2	0	0.3	0.3
C60	Penis	1	0	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0
C61	Prostate	154	0	0	0	0	0	0	0	0	0	0.2	0	2.8	6	18.7	39.3	60.5	114.1	2	5.8
C62	Testis	34	0	0	0.3	0	0	1.5	1.8	1	0.2	0.3	0	0	0.5	0	0	0	0	0.4	0.4
C63	Other male genital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C64	Kidney	64	0	0.4	0	0	0	0.4	0.3	0	0.5	0.4	1	1.1	4.1	4	4.4	6.4	19	0.8	1.2
C65	Renal Pelvis	3	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0.5	1.5	0	0	0	0.1
C66	Ureter	3	0	0	0	0	0	0	0	0	0	0	0.1	0.2	0	0	0	0	3.8	0	0.1
C67	Bladder	94	0	0.4	0	0	0	0	0.1	0.1	0.2	0.6	0.7	1.6	6.2	8.1	17.5	25.5	22.8	1.2	2.3
C68	Other Urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	5	0	1.1	0	0	0	0	0.1	0.1	0	0	0	0	0	0	0	0	0	0.1	0.2
C70-C72	Brain, Nervous system	51	0	0.8	0.3	0	0.4	0.4	0.7	0.3	0.5	0.3	0.3	1.3	2.4	1.5	4.4	3.2	0	0.7	0.8
C73	Thyroid	72	0	0	0.3	0	0	1.1	0.6	0.9	0.5	0.6	1.5	2.3	0.8	4.5	2.9	0	0	0.9	0.8
C74	Adrenal gland	4	0	0.4	0	0	0.4	0	0	0	0	0	0.1	0.2	0	0	0	0	0	0.1	0.1
C75	Other Endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C81	Hodgkin disease	52	0	0	0	0.4	1.3	0.7	1.3	0.8	0.6	0.4	0.6	0.8	1.4	0.5	1.5	0	0	0.7	0.6
C82-C85;C96	Non-Hodgkin lymphoma	131	0	0.4	1.2	1.1	0.9	2.2	1	0.8	0.9	0.8	1.8	2.8	5.4	6.6	5.8	9.5	22.8	1.7	2.3
C88	Immunoprolifera-tive dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	16	0	0	0	0	0	0	0.1	0	0.2	0.1	0.1	0.5	0.5	1.5	4.4	0	0	0.2	0.3
C91	Lymphoid Leukaemia	28	0	3	1.8	0.4	0.4	0.4	0.1	0.1	0	0.1	0.3	0	0.5	0.5	0	3.2	3.8	0.4	0.9
C92-C94	Myeloid Leukaemia	45	0	1.1	0.9	0.4	0.4	1.1	0.6	0	0.3	0.2	0.7	0.8	1.4	1.5	1.5	3.2	7.6	0.6	0.9
C95	Leukaemia unspec.	1	0	0	0	0	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other	Other & unspecified	71	0	0.4	0	0	0.4	0.7	0.7	0.3	0.3	0.5	0.6	1.5	3.5	6.6	7.3	3.2	11.4	0.9	1.3
All	All sites Total	1816	0	11	6	3	8	13	14	11	9	12	19	38	77	117	229	261	350	23.6	36.7
Not C44	All sites but C44	1679	0	11	6	3	7	13	13	10	9	11	18	35	69	107	207	239	323	21.8	33.9

Table 5.4.4: Age-Specific Incidence Rate (AIR), Age Standardised Incidence Rate (ASR) Among Non-Saudi Females (per 100,000) by Primary Site and Age groups, 2015

ICD(10th)	Site	All Ages	Age unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3.7	0	0	0	0.1
C01-C02	Tongue	10	0	0	0	0	0	0	0	0	0	0.2	0.4	2.1	3.3	2.3	7.4	0	9.7	0.3	0.8
C03-C06	Mouth	4	0	0	0	0	0	0	0	0	0	0	0.8	0	0	0	3.7	5.7	0	0.1	0.3
C07-C08	Salivary glands	4	0	0	0	0	0	0	0	0	0	0	0	0	1.6	2.3	3.7	5.7	0	0.1	0.4
C09	Tonsil	2	0	0	0	0	0	0	0	0	0.2	0.2	0	0	0	0	0	0	0	0.1	0
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C11	Nasopharynx	16	0	0.4	0	0	0	1	0.5	0.5	0.4	0.6	0.8	1.1	1.6	0	0	0	0	0.5	0.4
C12-C13	Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C14	Pharynx unspec.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Oesophagus	11	0	0	0	0	0	0	0	0	0.4	0	0.8	1.1	1.6	6.8	3.7	0	9.7	0.3	0.8
C16	Stomach	28	0	0	0	0	0	0	0.3	0.5	0.6	0	0.8	2.1	3.3	11.4	11.1	28.6	29	0.8	2.3
C17	Small intestine	8	0	0	0	0	0	0	0.3	0.3	0	0.2	1.2	1.1	0	2.3	0	0	0	0.2	0.3
C18	Colon	73	0	0	0	0	0.5	0	1.3	1	1.8	1.7	3.2	12.8	18	20.5	7.4	17.2	9.7	2.1	3.5
C19-C20	Rectum	32	0	0	0	0	0	0	0	0.8	0.8	0.9	1.2	4.3	6.5	9.1	18.5	0	9.7	0.9	1.8
C21	Anus	7	0	0	0	0	0	0	0.3	0.3	0	0	0.4	0	3.3	2.3	3.7	0	0	0.2	0.4
C22	Liver	14	0	0.4	0	0	0	0	0	0	0	0	0.8	2.1	0	9.1	0	11.5	29	0.4	1.4
C23-C24	Gallbladder etc.	14	0	0	0	0	0	0	0	0	0	0	1.2	1.1	4.9	6.8	7.4	11.5	0	0.4	1
C25	Pancreas	23	0	0.4	0	0	0	0	0	0.3	0.4	0.4	0.8	2.1	4.9	4.6	11.1	17.2	19.3	0.7	1.7
C30-C31	Nose, sinuses etc.	4	0	0	0	0	0	0	0.3	0	0	0.2	0	1.1	0	0	3.7	0	0	0.1	0.2
C32	Larynx	1	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0	0	0
C33-C34	Trachea,Brochus,Lung	32	0	0	0	0	0.5	0.5	0.3	0.5	0	0.9	0.4	4.3	9.8	9.1	7.4	17.2	29	0.9	2.3
C37-C38	Other Thoracic organs	2	0	0	0	0	0	0	0	0	0	0.2	0	0	0	2.3	0	0	0	0.1	0.1
C40-C41	Bone	12	0	0	0.3	0.8	0	0.5	0.8	0.5	0.2	0	0	1.1	0	0	0	0	9.7	0.3	0.5
C43	Melanoma of Skin	6	0	0	0	0	0	0	0	0	0.2	0.2	0.4	1.1	1.6	0	0	0	9.7	0.2	0.4
C44	Other Skin	41	0	0	0	0.4	1	0	0.3	0.8	0.4	0.4	1.6	6.4	14.7	2.3	14.8	17.2	29	1.2	2.7
C45	Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C46	Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C47,C49	Connective,Soft tissue	21	0	0	0	0.8	0.5	1.5	0.5	0.3	0.2	1.1	0.4	4.3	0	0	3.7	0	0	0.6	0.7
C50	Breast	698	0	0	0	0	0	2	6.5	10.6	17.7	26.7	46.9	114.2	132.2	111.8	118.4	74.5	125.6	19.9	29.8
C51	Vulva	2	0	0	0	0	0	0	0	0	0	0	0	2.1	0	0	0	0	0	0.1	0.1
C52	Vagina	4	0	0	0	0	0	0	0	0	0	0.4	0	1.1	1.6	0	0	0	0	0.1	0.1
C53	Cervix Uteri	47	0	0	0	0	0	0	0.5	0	1.2	0.9	4	8.5	14.7	9.1	3.7	5.7	19.3	1.3	2.4
C54	Corpus Uteri	81	0	0	0	0	0	0.5	0	0	1.4	1.9	4.8	12.8	19.6	25.1	37	17.2	38.7	2.3	5.2
C55	Uterus unspec.	14	0	0	0	0	0	0	0	0	0	0.2	0.8	3.2	4.9	4.6	3.7	5.7	9.7	0.4	1
C56	Ovary	63	0	0	0.3	0.4	0.5	0.5	1.3	1.5	0.4	1.7	3.2	6.4	9.8	6.8	18.5	28.6	48.3	1.8	3.7
C57	Other Female Genital	3	0	0	0	0	0	0	0	0.5	0	0	0	0	1.6	0	0	0	0	0.1	0.1
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C64	Kidney	30	0	0.8	0.6	0.4	0.5	1	0	0.5	0.2	0.4	2.4	4.3	3.3	6.8	0	5.7	9.7	0.9	1.5
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C67	Bladder	9	0	0	0	0	0	0	0	0	0	0	0	1.1	1.6	6.8	3.7	0	29	0.3	1.1
C68	Other Urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	5	0	0.8	0	0	0	0.5	0.3	0	0	0	0	0	0	0	0	0	9.7	0.1	0.4
C70-C72	Brain, Nervous system	29	0	2.4	0.3	0	0.5	0.5	0.3	0.8	0.6	0.6	1.2	2.1	1.6	6.8	0	5.7	0	0.8	1.2
C73	Thyroid	151	0	0.8	0	0	1	1.5	4.3	6.1	5.5	5.4	7.2	19.2	9.8	13.7	3.7	0	9.7	4.3	4.3
C74	Adrenal gland	3	0	0.8	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0	0.1	0.1
C75	Other Endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C81	Hodgkin disease	28	0	0	0	0	2.4	1.5	1.8	1	0.2	0.6	0.4	1.1	1.6	0	7.4	0	0	0.8	1
C82-C85,C96	Non-Hodgkin lymphoma	61	0	0	0.3	0.8	1.9	0.5	0.8	0.3	1.6	0.9	2.8	7.5	9.8	13.7	7.4	17.2	58	1.7	3.7
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	12	0	0	0	0	0	0	0	0	0.4	0	0	3.2	3.3	2.3	3.7	0	29	0.3	1.1
C91	Lymphoid Leukaemia	21	0	3.2	1.3	0.4	0	0	0.5	0	0.2	0.2	0	1.1	3.3	0	0	5.7	0	0.6	0.9
C92-C94	Myeloid Leukaemia	15	0	0	0	0	1	0	0	0.3	0.4	0.4	1.6	0	3.3	4.6	0	0	0	0.4	0.6
C95	Leukaemia unspec.	8	0	0	0.3	0	0	0	0.3	0.3	0.2	0.2	0	1.1	0	0	0	5.7	9.7	0.2	0.5
Other	Other & unspecified	38	0	0	0	0	0.5	0	0	0.5	1	1.1	2.8	4.3	8.2	6.8	7.4	22.9	0	1.1	1.9
All	All sites Total	1688	0	10	3	4	11	12	21	28	36	49	94	241	305	310	326	327	589	48.2	82.7
Not C44	All sites but C44	1647	0	10	3	3	10	12	21	27	36	49	93	235	291	308	311	309	560	47.1	80

Acknowledgment

We would like to express our deepest gratitude to the following members of SCR advisory committee and staff of the registry for their invaluable contribution and support.

SCR advisory committee Members

Dr. Ali Alzahrani (Chairman) Principal Clinical Scientist/ Senior Consultant Executive director, Gulf Center for Cancer Control and Prevention (KFSH&RC)	Dr. Sulieman Alshehri Consultant Public Health & Pediatrics General Director of Saudi National Cancer Center
Dr. Shouki Bazarbashi Head, Section of Medical Oncology, Oncology Center King Faisal Specialist Hospital & Research Center	Dr. Hani Alhashmi Director, Oncology Center, Consultant Medical Oncology, Hematology and Stem Cell Transplant
Dr. Hind Almutlaq Director of National Health Registries	Mr. Khaled Sharaheli Manager of Saudi Cancer Registry

Main Office

Dr. Hind Al-Mutlaq (Director of National Health Registries)
Mr. Khaled Sharaheli (Manager of Saudi Cancer Registry)
Mr. Zeyad Al-Shahrani
Mr. Ahmed Al-Rawaji
Mrs. Wafa Alzahrani
Mrs. Malak Al-Jamaan
Mr. Fawaz Alomran
Mrs. Ghadi Al-Gosaibi

Central Region

Dr. Mushabab Asiri - Regional Manager
Mr. Mohammed Hayder (CTR)
Mr. Mohamed Kamal Abdulqader (CTR)
Mr. Iman Daggal

Western Region

Dr. Hassnah Al-Ghamdi- Regional Manager
Mr. Sameer Kaifah
Mr. Ahmed Al-Nemari
Ms. Ittra Hiali
Mr. Waleed Al-Qahtani

Eastern Region

Prof. Hassan Al-Idrisi- Regional Manager
Mr. Abdulmajeed Alam
Mr. Ramesh Kumar

Madinah & Northern Region

Dr. Amal Al-Behani- Regional Manager
Mr. Yousef Abdulhadi (CTR)
Mr. Akram Zamzami

Southern Region

Dr. Abdurahman Al-Shehri- Regional Manager
Mr. Syed Zafar Iqbal
Mr. Saleh Al-Olyani

السرطانات العشرة الأكثر شيوعاً بين السعوديين لكلا الجنسين

احتل سرطان الثدي المرتبة الأولى (٢٠١٦ حالة) بنسبة ١٦,٧ % تلاه سرطان القولون والمستقيم (١٤٦٥ حالة) بنسبة ١٢,٢ % ثم سرطان الغدة الدرقية (١٠٢٠ حالة) بنسبة ٨,٥ % ثم السرطان الليمفاوي اللاهودجكن (٨٢٩ حالة) بنسبة ٦,٩ % ثم سرطان ابيضاض الدم (٧٠٢ حالة) بنسبة ٥,٨ % يليه السرطان الليمفاوي هودجكن (٤٣٦ حالة) بنسبة ٣,٦ % ثم سرطان الرئة (٤١٦ حالة) بنسبة ٣,٥ % يليه سرطان الرحم (٤٠٣ حالة) بنسبة ٣,٣ % ثم سرطان الكبد (٣٧٦ حالة) بنسبة ٣,١ % وأخيراً سرطان البروستات (٣٤٠ حالة) بنسبة ٢,٨ %.

السرطانات العشرة الأكثر شيوعاً بين الأطفال السعوديين لكلا الجنسين

احتل سرطان ابيضاض الدم المرتبة الأولى (٢٥٥ حالة) بنسبة ٣٥,٠ % تلاه سرطان الدماغ والجهاز العصبي والسرطان الليمفاوي اللاهودجكن (٨٩ حالة) بنسبة ١٢,٢ % لكل منهما، ثم السرطان الليمفاوي هودجكن (٦٦ حالة) بنسبة ٩,١ % ثم سرطان الكلى (٤٣ حالة) بنسبة ٥,٩ %، يليه سرطان العظام (٣٢ حالة) بنسبة ٤,٤ %، ثم سرطان الغدة الكظرية (٢٨ حالة) بنسبة ٣,٨ % ثم سرطان العين (٢٦ حالة) بنسبة ٣,٦ % يليه سرطان الانسجة الضامة (٢٣ حالة) بنسبة ٣,٢ %، وأخيراً سرطان المبيض (١٢ حالة) بنسبة ١,٦ %.

السرطانات العشرة الأكثر شيوعاً بين السعوديين لكلا الجنسين

الاناث	٦٥٨٤	%	الذكور	٥٤٥٤	%
الثدي	١٩٧٩	٣٠,١	القولون والمستقيم	٨١٠	١٤,٩
الغدة الدرقية	٧٩٣	١٢,٠	الليمفاوي اللاهودجكن	٥٠٣	٩,٢
القولون والمستقيم	٦٥٥	٩,٩	ابيضاض الدم	٤٠٨	٧,٥
الرحم	٤٠٣	٦,١	البروستات	٣٤٠	٦,٢
الليمفاوي اللاهودجكن	٣٦٦	٥,٠	الرئة	٣٢٤	٥,٩
ابيضاض الدم	٢٩٤	٤,٥	الكبد	٢٧٤	٥,٠
المبيض	٢٢٠	٣,٣	الليمفاوي هودجكن	٢٦٧	٤,٩
الليمفاوي هودجكن	١٦٩	٢,٦	الغدة الدرقية	٢٢٧	٤,٢
المعدة	١٣١	٢,٠	الكلى	١٩٩	٣,٦
الدماغ والجهاز العصبي	١٢٦	١,٩	الدماغ والجهاز العصبي	١٩٤	٣,٦

السرطانات العشرة الأكثر شيوعاً بين الأطفال السعوديين لكلا الجنسين

الاناث	٣٠٩	%	الذكور	٤١٨	%
ابيضاض الدم	١٠٩	٣٥,٣	ابيضاض الدم	١٤٦	٣٤,٨
الدماغ والجهاز العصبي	٣٨	١٢,٣	الليمفاوي اللاهودجكن	٦٦	١٥,٨
الليمفاوي هودجكن	٢٥	٨,١	الدماغ والجهاز العصبي	٥١	١٢,٢
الكلى	٢٤	٧,٨	الليمفاوي هودجكن	٤١	٩,٨
الليمفاوي اللاهودجكن	٢٣	٧,٤	الكلى	١٩	٤,٥
العظام	١٧	٥,٥	العظام	١٥	٣,٦
الغدة الكظرية	١٥	٤,٩	العين	١٥	٣,٦
المبيض	١٢	٣,٩	الانسجة الضامة	١٤	٣,٣
العين	١١	٣,٦	الغدة الكظرية	١٣	٣,١
الانسجة الضامة	٩	٢,٩	الكبد	٨	١,٩

السجل السعودي للأورام

أنشئ السجل السعودي للأورام في عام ١٤١٢ هـ (١٩٩٢م) بمستشفى الملك فيصل التخصصي ومركز الأبحاث تحت إشراف وزارة الصحة وبمشاركة من القطاعات الصحية الحكومية. يضم السجل خمسة فروع في مناطق المملكة وبدأ السجل نشاطه في جمع المعلومات من شهر يناير في عام ١٩٩٤ م، حيث يتم جمع وترميز البيانات وتدخل حسب النظام المعتمد من منظمة الصحة العالمية وتحلل البيانات بشكل دوري. يقوم السجل بتزويد الجهات المختصة والباحثين بمعلومات إحصائية وفق نموذج خاص على صفحة السجل في الموقع الرسمي للمجلس الصحي السعودي

<https://nhic.gov.sa/eServices/Pages/TumorRegistration.aspx>

أحصائيات السرطان لعام ٢٠١٥ م

بلغ إجمالي عدد حالات السرطان المكتشفة في عام ٢٠١٥ م و المسجلة من مختلف المرافق الصحية الحكومية والخاصة بالمملكة العربية السعودية ١٥,٥٤٢ حالة ، من بين هذه الحالات ١٢,٠٣٨ سعوديين بنسبة ٧٧,٥ % وغير سعوديين ٣,٥٠٤ بنسبة ٢٢,٥ %. وكان عدد حالات السرطان لدى السعوديين الذكور ٥,٤٥٤ حالة بنسبة أجمالية قدرها ٤٥,٣ % بينما بلغ عدد الحالات لدى الإناث السعوديات ٦,٥٨٤ حالة بنسبة أجمالية قدرها ٥٤,٧ %.

المجموع الكلي			سعوديين			غير سعوديين	
			ذكر	أنثى	المجموع	ذكر	أنثى
١٥,٥٤٢			٥,٤٥٤	٦,٥٨٤	١٢,٠٣٨	١,٨١٦	١,٦٨٨
							المجموع
							٣,٥٠٤

بلغ المعدل المعياري للإصابة بالسرطان بين الرجال ٧٠,٧ حالة لكل ١٠٠,٠٠٠ نسمة وبين النساء ٨٣,٣ حالة لكل ١٠٠,٠٠٠ نسمة.



**المملكة العربية السعودية
المجلس الصحي السعودي
المركز الوطني للمعلومات الصحية
السجل السعودي للأورام**

**تقرير معدل الإصابة بمرض
السرطان
٢٠١٥**



المملكة العربية السعودية
المجلس الصحي السعودي
المركز الوطني للمعلومات الصحية
السجل السعودي للأورام

تقرير معدل الإصابة بمرض السرطان
٢٠١٥